

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/089357 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/00**
- (21) International Application Number:  
PCT/US2004/010351
- (22) International Filing Date: 2 April 2004 (02.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/459,742 2 April 2003 (02.04.2003) US
- (71) Applicant (for all designated States except US): **RE-  
GENTS OF THE UNIVERSITY OF MINNESOTA**  
[US/US]; 450 McNamara Alumni Center, 200 Oak Street  
S.E., Minneapolis, MN 55455-2070 (US).
- (71) Applicants and  
(72) Inventors: **CARLSON, Robert, M.** [US/US]; 2231 East  
Third Street, Duluth, MN 55812 (US). **GIBSON, David, J.**  
[US/US]; 1339 Vallee Drive, Woodbury, NJ 08096 (US).
- (74) Agents: **CLISE, Timothy, B. et al.**; Schwegman, Lund-  
berg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN  
55402 (US).
- (81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.
- (84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished  
upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL

(57) Abstract: The present invention provides for pharmaceutical compositions that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides for a cosmetic formulation that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides a method of treating a fungal infection that includes administering (e.g., topically applying) an effective amount of the pharmaceutical composition to the tissue afflicted with the fungal infection, or the tissue at risk of being afflicted with the fungal infection.

WO 2004/089357 A2

## Anti-fungal Formulation of Triterpene and Essential Oil

### Background of the Invention

5       Fungi infect humans and are a major cause of human health problems. They also infect plants and cause enormous losses in agricultural productivity. One class of fungal infections of mammals are the dermatophytic infections. These are fungal infections of the hair,  
10       nails, and skin. They are caused by fungi called "dermatophytes," which include species belonging to the genera *Epidermophyton*, *Microsporum*, and *Trichophyton*. Among the species of dermatophytes are the following: *Microsporum canis*, which results in scalp and skin  
15       infections, mostly in children; *Microsporum gypseum*, which also results in scalp and skin infections in animals and humans; *Trichophyton tonsurans*, the major agent causing scalp ringworm; *Trichophyton rubrum*, causing skin, nail, hair, and scalp infections; and  
20       *Trichophyton mentagrophytes*, which can occur on all parts of the body surface. Other fungal infectious agents include the opportunists that are likely to infect immunodeficient persons. These include *Cryptococcus*, *Candida*, and *Aspergillus*.

25       Outer layers of plants such as leaf cuticles, fruit peels, and bark protect the plant against abrasion, prevent water loss, and protect against pathogenic microorganisms. Breaking through the plant protective outer layer is a prerequisite for a pathogen to enter  
30       the plant's internal tissues. Some studies have

suggested that penetration of the protective layer involves dissolution of the host cuticle by enzymes secreted by the pathogen. Nicholson, R.L. et al., in *The Fungal Spore and Disease Initiation in Plants and Animals*, eds. Cole, G.T., and Hoch, H.C., 1991, Plenum Press, New York, pp. 3-23.

Pentacyclic triterpenes are among the most common plant secondary metabolites, but their function in plants has not been fully understood. They are usually concentrated in the outermost layers such as plant cuticle, fruit peel, and bark.

Literature supplies examples of enzymes that can be inhibited by triterpenes, indicating the ability of triterpenes to act broadly in a non-specific mode on multiple targets. For example, Buchler et al. (Biochem. Biophys. Acta 1075, 206 (1991) showed inhibition of rat renal 11 $\beta$ -hydroxysteroid dehydrogenase. Koch et al. (Phytother, Res. 8, 109 (1994)) showed in vitro inhibition of adenosine deaminase. This leads to the hypothesis that pentacyclic triterpenoids in plant protective outer layers may protect against infection by inhibiting enzymes that would degrade the cuticle.

Betulin is a pentacyclic triterpenoid derived from the outer bark of paper birch trees (*Betula papyrifera*, *B. pendula*, *B. verucosa*, etc.). It can be present at concentrations of up to about 24% of the bark of white birch. Merck Index, twelfth edition, page 1236 (1996). Lupeol is a related compound also found in birch bark and in other plant sources. Lupeol is present at

concentrations of about 1.5-3% of the birch bark and at up to about 8.2% in *Canavalia ensiformis*, a plant widespread in the humid tropics of Asia and Africa. Allobetulin is another triterpenoid found in birch bark.

5 A typical pulp mill that process birch produces enough bark waste to allow for the inexpensive isolation of significant quantities of these triterpenoids.

Several triterpenoids have been found to have utility. For example, betulin and related compounds

10 have been shown to have anti-viral activity against herpes simplex virus. Carlson et al., U.S. Patent No. 5,750,578. Betulin and related compounds have also been shown to have anti-fungal and anti-bacterial activity. However, triterpenoids are hydrophobic compounds with

15 relatively low interfacial activity and water solubility. For instance, the solubility of betulin in water is about 0.15 mg/l. The relatively low interfacial activity and water solubility can make handling and administration of the compounds difficult.

20 Low interfacial activity also limits the efficient interaction with target (fungi or bacteria) cell membranes. It also limits accessibility to hydrophilic biological targets or targets protected by a hydrophilic barrier.

25 Current agents used to treat fungal infections include the polyene antibiotics, including nystatin; synthetic azoles; and griseofulvin. Fungal infections are difficult to treat because, like humans, they are eukaryotes.

Although many triterpenes have biological activity, the use of triterpenes, particularly for treating plants, presents several drawbacks. Triterpenes dissolve sparingly in water and other aqueous media and thus are difficult to apply to crops in non-emulsion formulations.

Currently, there is a need for new anti-fungal compositions that include triterpenes. The new anti-fungal compositions would include a triterpene in a carrier that could effectively dissolve an effective and safe amount of the triterpene. A need particularly exists for compositions that will act against a range of species, including dermatophytic fungi. New anti-fungal compositions would be less expensive to manufacture if they were abundant natural products or easily synthesized from abundant natural products. As such, the compositions would have biological activity against a range of species, including dermatophytic fungi.

20

#### Summary of the Invention

The present invention provides for new anti-fungal compositions that include triterpenes. The new anti-fungal compositions include a triterpene in a carrier that effectively dissolves an effective and safe amount of the triterpene. The compositions act against a range of species, including dermatophytic fungi. The anti-fungal compositions are less expensive to manufacture or include triterpenes that are easily synthesized from abundant natural products. As such, the compositions

would have biological activity against a range of species, including dermatophytic fungi.

The present invention provides a pharmaceutical composition that includes a triterpene and an essential  
5 oil.

The present invention provides a cosmetic composition that includes a triterpene and an essential oil.

The present invention also provides an anti-  
10 fungicidal composition that includes a composition of the present invention and a fungicidal excipient.

The present invention also provides a therapeutic method for treating a mammal afflicted with a fungal infection that includes administering to the mammal, an  
15 effective anti-fungal amount of a composition of the present invention.

The present invention also provides a cosmetic method for alleviating the physical symptoms associated with a mammalian fungal infection, that includes  
20 administering to the mammal, an effective anti-fungal amount of a composition of the present invention.

The present invention also provides a method of inhibiting or killing a fungus that includes contacting the fungus with an effective anti-fungal amount of a  
25 composition of the present invention.

#### Detailed Description of the Invention

The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or  
30 iodo. Alkyl, alkoxy, alkenyl, etc. denote both straight

and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. Aryl  
5 denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.

It will be appreciated by those skilled in the art that triterpene compounds present in the compositions of  
10 the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or  
15 stereoisomeric form, or mixtures thereof, of a compound present in the compositions of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by  
20 recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine antifungal activity using the standard tests described herein, or  
25 using other similar tests which are well known in the art.

Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other

values within defined ranges for the radicals and substituents.

Specifically, (C<sub>1</sub>-C<sub>6</sub>)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl,  
5 3-pentyl, or hexyl;

partially unsaturated (C<sub>2</sub>-C<sub>6</sub>)alkyl or (C<sub>2</sub>-C<sub>6</sub>)alkenyl can be vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl,  
10 or 5-hexenyl;

(C<sub>1</sub>-C<sub>5</sub>)alkanoyl can be carbonyl, acetyl, propanoyl, butanoyl, isopropanoyl, or pentenoyl;

(C<sub>1</sub>-C<sub>6</sub>)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 2-pentoxy, 3-pentoxy, or hexyloxy;  
15

halo(C<sub>1</sub>-C<sub>6</sub>)alkoxy can be trifluoromethyloxy, 2-chloroethyloxy, 3,3-dichloropropoxyloxy, or 4,4,4-trifluorobutyloxy;

(C<sub>3</sub>-C<sub>8</sub>)cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl;  
20

(C<sub>3</sub>-C<sub>8</sub>)cycloalkyloxy can be cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, or cyclooctyloxy;

hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkoxy can be hydroxymethoxy, 1-hydroxyethoxy, 2-hydroxyethoxy, 1-hydroxypropoxy, 2-hydroxypropoxy, 3-hydroxypropoxy, 1-hydroxybutoxy, 4-hydroxybutoxy, 1-hydroxypentoxy, 5-hydroxypentoxy, 1-hydroxyhexoxy, or 6-hydroxyhexoxy;  
25

amino(C<sub>1</sub>-C<sub>6</sub>)alkyl can be aminomethyl, 1-aminoethyl, 2-aminoethyl, 1-aminopropyl, 2-aminopropyl, 3-  
30



aminopropyl, 1-aminobutyl, 2-aminobutyl, 3-aminobutyl, 4-aminobutyl, 1-aminopentyl, 2-aminopentyl, 3-aminopentyl, 5-aminopentyl, 1-aminohexyl, 2-aminohexyl, 3-aminohexyl, or 6-aminohexyl;

5 (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl, 2-methylpropyloxycarbonyl, butyloxycarbonyl, pentyloxycarbonyl, or hexyloxycarbonyl;

(C<sub>1</sub>-C<sub>6</sub>)alkanoyloxy can be carbonyloxy, acetyloxy, 10 propanoyloxy, butanoyloxy, 2-methylpropanoyloxy, 2-methylbutanoyloxy, 3-methylbutanoyloxy, pentanoyloxy, or hexanoyloxy.

"N<sup>+</sup>-containing heteroaryl" can be N-pyridinium, N-methyl-2-pyridinium, N-methyl-3-pyridinium, N-methyl-4-pyridinium, N-ethyl-2-pyridinium, N-ethyl-3-pyridinium, 15 N-ethyl-4-pyridinium, 3,5-dimethylpyridinium, or 4-(dimethylamino)pyridinium.

"N<sup>+</sup>-containing heterocycle" can be N-diazabicyclo[2.2.2]octyl; N-azabicyclo[2.2.2]octyl; N-20 methyl-N-piperidino; N,N-dimethyl-2-piperidino; N,N-dimethyl-3-piperidino; N,N-dimethyl-4-piperidino; N-methyl-N-morpholino; N,N-dimethyl-2-morpholino; or N,N-dimethyl-3-morpholino.

"-N<sup>+</sup>-R<sub>a</sub>R<sub>b</sub>R<sub>c</sub>" can be N'-benzyl-N,N,N',N'-25 tetramethylethylenediamine-N-yl; N,N,N',N'-tetramethylethylenediamine-N-yl; octyldimethylammonium; tetradecyldimethylammonium; trimethylammonium; triethylammonium, or tri(hydroxymethyl)ammonium.

"3-Carboxypropenoyloxymethyl" refers to the 30 structure

-CH<sub>2</sub>OC(=O)CH=CHCOOH.

"Aminoacetoxymethyl" refers to the structure

-CH<sub>2</sub>OC(=O)CH<sub>2</sub>NH<sub>2</sub>.

"(Carboxymethoxy)acetoxymethyl" refers to the  
5 structure

-CH<sub>2</sub>OC(=O)CH<sub>2</sub>OCH<sub>2</sub>COOH.

"4-Carboxybutanoyloxymethyl" refers to the  
structure

-CH<sub>2</sub>OC(=O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>COOH.

10 "3-Carboxypropanoyloxymethyl" refers to the  
structure

-CH<sub>2</sub>OC(=O)CH<sub>2</sub>CH<sub>2</sub>COOH.

"Carboxycarbonyloxymethyl" refers to the structure


-CH<sub>2</sub>OC(=O)COOH.

15 "2-Amino-3-methyl-butanoyloxymethyl" refers to the  
structure

-CH<sub>2</sub>OC(=O)CH(NH<sub>2</sub>)CH(CH<sub>3</sub>)<sub>2</sub>.

"4-Carboxy-(3,3-dimethyl)butanoyloxymethyl" refers  
to the structure -CH<sub>2</sub>OC(=O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>COOH.


20 "2-Carboxybenzoyloxymethyl" refers to the structure



"Butanoyloxymethyl" refers to the structure

-CH<sub>2</sub>OC(=O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.

25 "2-Carboxybenzoyl" refers to the structure



"2-Amino-3-methylbutanoyl" refers to the structure  
 $-C(=O)CH_2(NH_2)CH_2(CH_3)_2$ .


"3-Carboxypropenoyl" refers to the structure  
 5  $-C(=O)CH=CHCOOH$ .

"Aminoacetyl" refers to the structure  $-C(=O)CH_2NH_2$ .

"4-Carboxybutanoyl" refers to the structure  
 $-C(=O)CH_2CH_2CH_2COOH$ .

"(Carboxymethoxy)acetyl" refers to the structure  
 10  $-C(=O)CH_2OCH_2COOH$ .

"3-(3,4-Dihydroxyphenyl)propenoyl" refers to the structure



"3-Carboxypropanoyl" refers to the structure  
 15  $-C(=O)CH_2CH_2COOH$ .

"Carboxycarbonyl" refers to the structure -  
 $C(=O)COOH$ .

"4-Carboxy-(3,3-dimethyl)butanoyl" refers to the structure

$-\text{C}(=\text{O})\text{CH}_2\text{C}(\text{CH}_3)_2\text{CH}_2\text{COOH}$ .

"Carboxymethylenethioacetyl" refers to the structure  $-\text{C}(=\text{O})\text{CH}_2\text{SCH}_2\text{COOH}$ .

"3-Carboxy-3-methylbutanoyl" refers to the  
5 structure  $-\text{C}(=\text{O})\text{CH}_2\text{C}(\text{COOH})(\text{CH}_3)_2$ .

The term "amino acid," comprises the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as  
10 well as unnatural amino acids (e.g. phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,- tetrahydroisoquinoline-3-carboxylic acid, penicillamine,  
15 ornithine, citruline,  $\alpha$ -methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine). The term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g. acetyl or  
20 benzyloxycarbonyl), as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a  $(\text{C}_1\text{-C}_6)$ alkyl, phenyl or benzyl ester or amide; or as an  $\alpha$ -methylbenzyl amide). Other suitable amino and carboxy protecting groups are known to those skilled in the art  
25 (See for example, T.W. Greene, *Protecting Groups In Organic Synthesis*; Third Edition, Wiley: New York, 1999, and references cited therein). An amino acid can be linked to the remainder of a compound of formula (I)-(VI) through the carboxy terminus, the amino terminus,

or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.

The term "peptide" describes a sequence of 2 to 25 amino acids (e.g. as defined hereinabove) or peptidyl  
5 residues. The sequence may be linear or cyclic. For example, a cyclic peptide can be prepared or may result from the formation of disulfide bridges between two cysteine residues in a sequence. A peptide can be linked to the remainder of a compound of formula (I)-  
10 (VI) through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of a cysteine. Preferably a peptide comprises 3 to 25, or 5 to 21 amino acids. Peptide derivatives can be prepared as disclosed  
15 in U.S. Patent Numbers 4,612,302; 4,853,371; and 4,684,620.

Glycosides are formed by reacting mono-, di- and polysaccharides with 1-2 hydroxyl groups of the compound of formula (I)-(VI), including glucose, glucuronic acid,  
20 mannose, galactose, sorbose, ribose, maltose, sucrose, modified cellulose, dextrans, modified starches and the like. These derivatives can advantageously exhibit improved water solubility over betulin itself. See, *Remington's Pharmaceutical Sciences*, A. R. Gennaro, ed.,  
25 Mack Pub. Co. (18th ed., 1990) at pages 384-386. Glycoside derivatives can be prepared as described in PCT Applications WO 96/34005 and 97/03995.

The term "polyethyleneimine" refers to the group  $(-NHCH_2CH_2-)_x[-N(CH_2CH_2NH_2)CH_2CH_2-]_y$ . Polyethyleneimine can  
30 be attached to a compound through either of the nitrogen

atoms marked with hash marks. "Poly(ethylene glycol)" refers to the compound  $\text{H}(\text{OCH}_2\text{CH}_2)_n\text{OH}$ . It can be attached to a compound through its terminal hydroxyl.

The term "partially unsaturated" refers to a linear  
5 or branched hydrocarbon having one or more carbon-carbon double bonds.

The term "phosphono" refers to  $\text{O}=\text{P}(\text{OH})_2-$ .

The term "direct bond" refers to a group being absent.

10 Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound" is meant herein a compound that is sufficiently robust to survive  
isolation to a useful degree of purity from a reaction  
15 mixture, and formulation into an efficacious antifungal agent.

As used herein, the term "triterpene" can be a plant secondary metabolite that includes a hydrocarbon, or its oxygenated analog, that is derived from squalene  
20 by a sequence of straightforward cyclizations, functionalizations, and sometimes rearrangement. Triterpenes or analogues thereof can be prepared by methods known in the art, i.e., using conventional synthetic techniques or by isolation from plants.  
25 Suitable exemplary triterpenes and the biological synthesis of the same are disclosed, e.g., in R.B. Herbert, The Biosynthesis of Secondary Plant Metabolites, 2nd. ed. (London: Chapman 1989). The term  
"triterpene" refers to one of a class of compounds  
30 having approximately 30 carbon atoms and synthesized

from six isoprene units in plants and other organisms. Triterpenes consist of carbon, hydrogen, and optionally oxygen. Most triterpenes are secondary metabolites in plants. Most, but not all, triterpenes are pentacyclic.

5 Examples of triterpenes include betulin, allobetulin, lupeol, friedelin, and all sterols, including lanosterol, stigmasterol, cholesterol,  $\beta$ -sitosterol, and ergosterol.

The term, "essential oil" refers to a highly

10 odoriferous, volatile liquid component obtained from plant tissue. Essential oils typically include a mixture of one or more terpenes, esters, aldehydes, ketones, alcohols, phenols, and/or oxides. These functional classes of compounds are responsible for the

15 therapeutic properties and distinct fragrance of the essential oil.

The essential oil can be manufactured (i.e., synthesized or partially synthesized). Alternatively, the essential oil can be obtained from a plant or plant

20 component (e.g., plant tissue). Suitable plant or plant components include, e.g., a herb, flower, fruit, seed, bark, stem, root, needle, bulb, berry, rhizome, rootstock, leaf, or a combination thereof.

Any suitable essential oil can be employed provided

25 (1) the essential oil has therapeutic properties (e.g., the essential oil has anti-fungal properties), (2) the essential oil provides a scent that is associated with plant tissue, (3) the essential oil remains stable in the composition, and/or the essential oil at least

30 partially dissolves the triterpene. Preferably, the

stability is over a prolonged period of time, e.g., up to about 3 years, up to about 1 year, or up to about 6 months, typically experienced in the manufacturing, packaging, shipping, and/or storage of the composition.

- 5 The specific essential oil will preferably be non-toxic to mammals (e.g., humans) and will be suitable for medicinal use (e.g., topically). The specific essential oil will also preferably comply with any controlling or governing body of law, e.g., FDA regulations.

- 10 Suitable specific essential oils include, e.g., one or more of the following: ajowan, sweet almond oil, allspice, aloe vera oil, ammi visnaga (khella), amyris, angelica root, angelica seed, anise, anise seed, star anise, apricot kernel oil, absolute arnica, avocado oil, 15 unrefined avocado oil, Copaiba balsam, balsam Peru genuine, balsam Peru oil, balsam peru liquid resin, balsam tolu, sweet french basil, basil, basil ct. methyl chavicol, lemon ct. citral basil, sweet ct. linalool basil, bay laurel, bay leaf, bay rum, bay leaf West 20 Indies, bees wax, unrefined bees wax, benzoin absolute, benzoin resinoid, bergamot, mint bergamot, Italian bergamot oil, free bergaptene bergamot, birch, sweet birch, borage oil, boronia, butter, buchu leaf, cajeput, calamus, calendula oil, infused calendula oil, camellia 25 oil, cannabis, caraway, caraway seed, cardamom, absolute carnation, carrot seed, high carotol carrot seed, carrot seed oil, cassia, cassis bud (black currant), castor oil, catnip, oil of catnip, cedarleaf, western red cedarleaf, cedarwood, Atlas cedarwood, Himalayan 30 cedarwood, Virginia cedarwood, celery seed, chamomile,



- blue chamomile, German chamomile, Moroccan chamomile,  
Moroccan wild chamomile, Roman chamomile, champaca,  
cilantro, true cinnamon bark, cinnamon bark, cinnamon  
leaf, cinnamon cassia, cistus, citronella, Java  
5 citronella, ciste oil, artificial civet, clary sage,  
high sclareol clary sage, clementine, Italian clementine  
peel oil, clove, clove bud, clove leaf, cocoa, cocoa  
butter, unrefined cocoa butter, coconut oil, refined  
coconut oil, cognac, combava petitgrain, coriander,  
10 green coriander, cornmint, costus oil, cumin, cypress,  
davana oil, dill, dill weed, elemi, erigeron (fleabane),  
eucalyptus citriodora, eucalyptus globulus, lemon  
eucalyptus, fennel, sweet fennel, fenugreek, fir, Canada  
fir needle, Siberia fir needle, white fir needle,  
15 frankincense, India frankincense, Oman frankincense,  
galbanum oil, garlic, genet, geranium, geranium leaf,  
geranium rose, Bourbon geranium, Egyptian geranium,  
ginger, Cochin extra ginger, ginseng, Siberian ginseng,  
Korean ginseng, grapefruit, pink grapefruit, white  
20 grapefruit, grapeseed oil, hazelnut oil, helichrysum,  
helichrysum immortelle, Mad. helichrysum, Balkan  
helichrysum, Corsica helichrysum, France helichrysum,  
hemp oil, absolute honeysuckle, hyssop, hyssop  
decumbens, absolute immortelle, fragrant aster inula,  
25 Jamaican gold, unrefined Jamaican gold, jasmine,  
absolute jasmine, grandiflorum jasmine, sambac jasmine,  
jojoba oil, helio-carrot in jojoba, melissa in jojoba,  
absolute jonquille, juniper berry, Siberia juniper  
berry, Croatia juniper berry, lanolin, unrefined  
30 anhydrous lanolin, lantana camara, laurel nobilis,

lavandin, abrialis lavandin, grosso lavandin, lavender,  
Oregon lavender, Bulgarian lavender, Russian lavender,  
high-altitude lavendar, wild-crafted lavender, lavandin,  
organic lavandin, lemon, lemongrass, lime, distilled  
5 lime, expressed lime, litsea, litsea cubeba, blue, pink  
and white lotus, macadamia oil, mace, green mandarin,  
red mandarin, yellow mandarin, manuka, absolute  
marigold, marigold flower, marjoram, Spanish marjoram,  
sweet marjoram (true), massoia bark, melissa,  
10 codistilled melissa, "rectified" melissa, true melissa,  
absolute mimosa, mimosa, monarda, mugwort, musk seed,  
myrrh, myrtle, absolute narcissus, neroli (orange  
blossom), niaouli, nutmeg, extra nutmeg, oakmoss,  
absolute oak moss, olibanum, absolute opopanax, bitter  
15 orange, blood orange, sweet orange, wild West Indian  
orange, oregano, orris root, concrete orris, osmanthus,  
palm oil, refined palm oil, palmarosa, paprika, parsley  
seed, patchouli, Indian patchouli oil, Indonesian  
patchouli oil, peanut, peanut oil, pecan oil,  
20 pennyroyal, pepper, black pepper, super black pepper,  
peppermint, India peppermint, USA baby mint peppermint,  
pet perfume, petitgrain (orange leaves), white pine,  
pine needle, evening primrose, ravensara anisata, true  
ravensara, ravensare, ravintsara, redberry, rosalina,  
25 rose, rose geranium, rose otto, Bulgarian rose, English  
rose, Turkish rose, rosehip seed oil, rosemary, rosemary  
anti-oxidant extract powder, rosemary verbenone, Morocco  
rosemary, Spain rosemary, rosewood, rosewood oil, rue,  
sage, white sage, sage dalmatian, sage officinalis, sage  
30 triloba, sandalwood, seabuckthorn berry, sesame oil,

sesame seed oil, shea butter, unrefined shea butter, spikenard, green spikenard, spruce, St. John's wort, styrax resin, tagetes, tangerine, Dancy tangerine, tarragon, tea tree, Australia tea tree, thuja (cedar  
5 leaf), thyme, red thyme, thyme ct. linalool, thyme vulgaris, wild thyme, red thyme, mixed tocopherols, tolu balsam resin, absolute tuberose, tuberose, tumeric, valerian, vanilla, pure vanilla extract, vanilla bean, absolute vanilla bourbon, vegetable glycerin, absolute  
10 verbena, vetiver, violete leaves, vitex, organic Haiti vetiver, absolute violet leaf, walnut oil, wintergreen, natural wintergreen, wormwood, yarrow, ylang ylang, ylang ylang I, ylang ylang II, ylang ylang III, ylang ylang compound, ylang ylang complete, and ylang ylang  
15 extra.

Specifically, suitable exemplary essential oils include, e.g., angelica root, anise, basil (e.g., sweet French basil), bay leaf, benzoin absolute, bergamot, birch, carrot seed, cedarwood, chamomile (e.g., German  
20 chamomile, Moroccan chamomile, or Roman chamomile), cinnamon leaf, cinnamon cassia, cistus, citronella, clary sage, clove bud, cypress, eucalyptus globulus, eucalyptus citriodora, everlasting (helicrysum), fennel, fir, frankincense, geranium, ginger, grapefruit,  
25 helichrysum, hyssop, juniper berry, lavender, lavandin, lemon, lemongrass, lime, marjoram, myrrh, myrtle, neroli, niaouli, nutmeg, sweet orange, oregano, patchouli, pennyroyal, peppermint, petitgrain, pepper, pine needle, ravensare, rose geranium, rosemary (e.g.,  
30 Spanish rosemary), rosewood, sage, sandalwood,

spikenard, spruce, tangerine, tarragon, tea tree, thyme, vanilla, vetiver, ylang ylang, or a combination thereof.

In one specific embodiment of the present invention, the essential oil can include, e.g., the  
5 combination of menthol, camphor, eucalyptus oil, cedarleaf oil, nutmeg oil, thymol, and turpentine oil. In another specific embodiment of the present invention, the essential oil can exclude, e.g., the combination of menthol, camphor, eucalyptus oil, cedarleaf oil, nutmeg  
10 oil, thymol, and turpentine oil.

In one specific embodiment of the present invention, the essential oil includes Vicks® Vapor Rub. It has surprisingly been discovered that Vicks® Vapor Rub effectively solubilizes an effective anti-fungal  
15 amount of a triterpene (e.g., betulin), while maintaining the stability and anti-fungal activity of the triterpene.

Other suitable essential oils that can be employed in the compositions of the present invention are  
20 disclosed in the following websites: [www.essential-essences.com](http://www.essential-essences.com); [www.fragrancefactory.com](http://www.fragrancefactory.com); [www.essentialoil.com](http://www.essentialoil.com); [www.essentialoils.org](http://www.essentialoils.org); [www.halcyon.com](http://www.halcyon.com); and [www.essential-oil.org](http://www.essential-oil.org); which are all incorporated by reference herein.

25 The term "quaternary ammonium salt" refers to a compound comprising at least one positively charged nitrogen atom with four covalent bonds to non-hydrogen atoms. Typically the four bonds will be to carbon atoms. Two or three of the bonds can make up a double  
30 or triple bond respectively to a single atom.

The triterpenes present in the compositions of the instant invention also include triterpenes derivatized with  $N^+$ -containing groups. These compounds are found to be rather resistant to hydrolysis. Derivatization with


5  $N^+$ -containing groups is also found to make the triterpenes present in the compositions of the instant invention rather water soluble. For instance, the solubility of some quaternary salts of betulin disclosed herein is 400-600 g/l.

10 The term "quaternary ammonium salt of a triterpene" refers to triterpene covalently attached to a group comprising at least one positively charged nitrogen atom with four covalent bonds to non-hydrogen atoms. Examples of quaternary ammonium salts of a triterpene


15 include a compound of formulas (I)-(IV).

The term "fungus" refers to a distinct group of eukaryotic, spore-forming organisms with absorptive nutrition and lacking chlorophyll. It includes mushrooms, molds, and yeasts.

20 The term "N-diazabicyclo[2.2.2]octyl" refers to the group




25 The term "N-pyridinium" refers to the group




The term "N-methyl-N-piperidino" refers to the group

5




The term "N-methyl-N-morpholino" refers to the group

10




The term "N-azabicyclo[2.2.2]octyl" refers to the group


15



The structure and carbon numbering of three exemplary compounds present in the compositions of the



instant invention are shown below.



Lupeol

Specific values for compounds of formula (I) are as follows.

A specific value for the bond between carbons 1 and 2 is a single bond.

5 Another specific value for the bond between carbons 1 and 2 is a double bond.

A specific value for  $R_1$  is hydrogen.

Another specific value for  $R_1$  is hydroxy.

A specific value for  $R_2$  is a direct bond.

10 A specific value for  $R_3$  is  $(C_1-C_6)$ alkyl; wherein any alkyl can optionally be substituted with one or more oxo, carboxy, amino,  $-OP(=O)(OH)_2$ , or phenyl; any alkyl is optionally interrupted on carbon with one or more oxy or thio; any alkyl is optionally partially unsaturated;  
15 and any aryl can optionally be substituted with one or more hydroxy or carboxy.

Another specific value for  $R_3$  is hydroxymethyl, (carboxymethoxy)acetoxymethyl, 4-



- carboxybutanoyloxymethyl, 3-carboxypropenoyloxymethyl, 2-carboxybenzoyloxymethyl, 3-carboxypropanoyloxymethyl, aminoacetoxymethyl, carboxycarbonyloxymethyl, 2-amino-3-methyl-butanoyloxymethyl, 4-carboxy-(3,3-
- 5 dimethyl)butanoyloxymethyl, or
- $-\text{CH}_2\text{OC}(=\text{O})\text{C}(=\text{O})-(\text{-NHCH}_2\text{CH}_2)_x-[\text{-N}(\text{CH}_2\text{CH}_2\text{NH}_2)\text{CH}_2\text{CH}_2]_y$ .

A specific value for  $R_4$  is hydrogen or  $(\text{C}_1\text{-C}_6)$ alkyl; wherein any alkyl can optionally be substituted with one or more oxo, carboxy, amino,  $-\text{OP}(=\text{O})(\text{OH})_2$ , or phenyl;

10 any alkyl is optionally interrupted on carbon with one or more oxy or thio; any alkyl is optionally partially unsaturated; and any aryl can optionally be substituted with one or more hydroxy or carboxy.

- Another specific value for  $R_4$  is hydrogen,
- 15 hydroxymethyl, (carboxymethoxy)acetyl, 4-carboxybutanoyl, 3-carboxypropenoyl, 2-carboxybenzoyl, 3-carboxypropanoyl, aminoacetyl, carboxycarbonyl, 2-amino-3-methyl-butanoyl, 4-carboxy-(3,3-dimethyl)butanoyl, 3-carboxy-3-methylbutanoyl or -
- 20  $\text{C}(=\text{O})\text{C}(=\text{O})-(\text{-NHCH}_2\text{CH}_2)_x-[\text{-N}(\text{CH}_2\text{CH}_2\text{NH}_2)\text{CH}_2\text{CH}_2]_y$ .

A specific value for  $R_5$  is oxy.

A specific group of compounds are compounds of formula (I) wherein  $R_1$  is hydrogen or hydroxy;  $R_2$  is a direct bond;  $R_3$  is  $(\text{C}_1\text{-C}_6)$ alkyl;  $R_4$  is hydrogen or  $(\text{C}_1\text{-C}_6)$ alkyl; and  $R_5$  is oxy or  $R_4$  and  $R_5$  together are oxo;

25 wherein any alkyl can optionally be substituted with one or more oxo, carboxy, amino, or  $-\text{OP}(=\text{O})(\text{OH})_2$ , or phenyl; any alkyl is optionally interrupted on carbon with one or more oxy or thio; any alkyl is optionally partially

unsaturated; and any aryl can optionally be substituted with one or more hydroxy or carboxy.

Another specific group of compounds are compounds of formula (I) wherein  $R_1$  is hydrogen or hydroxy;  $R_2$  is a direct bond;  $R_3$  is hydroxymethyl, (carboxymethoxy)acetoxymethyl, 4-carboxybutanoyloxymethyl, 3-carboxypropenoyloxymethyl, 2-carboxybenzoyloxymethyl, 3-carboxypropanoyloxymethyl, aminoacetoxymethyl, carboxycarbonyloxymethyl, 2-amino-3-methyl-butanoyloxymethyl, 4-carboxy-(3,3-dimethyl)butanoyloxymethyl, or  $-\text{CH}_2\text{OC}(=\text{O})\text{C}(=\text{O})-(\text{-NHCH}_2\text{CH}_2)_x-$   $[-\text{N}(\text{CH}_2\text{CH}_2\text{NH}_2)\text{CH}_2\text{CH}_2]_y$ ;  $R_4$  is hydrogen, hydroxymethyl, (carboxymethoxy)acetyl, 4-carboxybutanoyl, 3-carboxypropenoyl, 2-carboxybenzoyl, 3-carboxypropanoyl, aminoacetyl, carboxycarbonyl, 2-amino-3-methyl-butanoyl, 4-carboxy-(3,3-dimethyl)butanoyl, 3-carboxy-3-methylbutanoyl or  $-\text{C}(=\text{O})\text{C}(=\text{O})-(\text{-NHCH}_2\text{CH}_2)_x-$   $[-\text{N}(\text{CH}_2\text{CH}_2\text{NH}_2)\text{CH}_2\text{CH}_2]_y$ ; and  $R_5$  is oxy or  $R_4$  and  $R_5$  together are oxo.

Another specific group of compounds of formula (I) is betulin; betulin-3,28-diglycine; betulin-28-glycerol oxalate; betulin-28-glycine; betulin-28-oxalate; betulin arabinose galactan; betulin-3,28-diglycolate; betulin-3-maleate; betulin-3,28-di-(L-glutamic acid  $\gamma$ -benzylester) ester; betulin-3,28-di-L-alanine; betulin-3,28-di-L-proline ester; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-diphenylalanine; betulin-3,28-di-(L-proline ester); betulin-3,28-dioxalate-polyethylene amine; betulin-3,28-diphosphate; betulin-3-caffeate;

betulin-3,28-(3',3'-dimethyl)glutarate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-maleate; betulin-28-phthalate; betulin-3,28-di(3',3'-dimethyl)glutarate; betulin-3,28-didiglycolate; betulin-3,28-  
 5 dithiodiglycolate; betulin-3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-L-valine ester; betulin-28-succinate; betulin-3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH (Mw=1448); betulin-3,28-di-  
 10 (polyethylene glycol)-COOH (Mw=906 crude); betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 pure); betulinic acid; betulon-1-ene-2-ol; betulin-3,28-(dipoly(ethylene glycol)bis (carboxymethylester); hederin hydrate; lupeol; lupeol-3-glutarate; lupeol-3-succinate; lupeol-  
 15 3-thiodiglycolate; lupeol-3-phthalate; oleanolic acid; ursolic acid; or uvaol.

Another specific group of compounds of formula (I) is betulin; betulin-3,28-diglycine; betulin-28-glycerol oxalate; betulin-28-glycine; betulin oxalate; betulin  
 20 arabinose galactan; betulin-3,28-diglycolate; betulin-3-maleate; betulin di-(L-glutamic acid  $\gamma$ -benzylester) ester; betulin 3,28-di-L-alanine; betulin3,28-di-L-proline; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-diphenylalanine ester; betulin-3,28-  
 25 dioxalate-(polyethylene amine); betulin-3-caffeate; betulin-3,28-(3',3'-dimethyl)glutarate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-phthalate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-phosphate; betulin-28-succinate; betulin-  
 30 3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-

COOH (Mw=1448); betulin-3,28-di-(polyethylene glycol)-  
COOH (Mw=906 crude); betulin-3,28-di-(polyethylene  
glycol)-COOH (Mw=906 pure); betulon-1-ene-2-ol; betulin-  
3,28-(dipoly(ethylene glycol)bis(carboxymethylester));  
5 hederin hydrate; lupeol-3-succinate; lupeol-3-phthalate;  
lupeol-3-glutarate; oleanolic acid; ursolic acid; or  
uvaol.

Another specific group of compounds of formula (I)  
is betulin; betulin-3-maleate; betulin-28-diglycolate;  
10 betulin-28-glutarate; betulin-28-maleate; betulin-28-  
phthalate; betulin-28-succinate; betulin-3,28-diglycine;  
betulin-3,28-didiglycolate; betulin-3,28-dimaleate;  
betulin-3,28-dioxalate-3-polyethyleneimine; betulin-  
3,28-di(3',3'-dimethyl)glutarate; betulin-3,28-  
15 dioxalate-3,28-polyethyleneimine; betulin-3,28-  
diphthalate; betulin-3,28-disuccinate; betulin-3,28-di-  
L-valine; lupeol; lupeol-3-amine; lupeol-3-(3',3'-  
dimethyl)succinate; lupeol-3-maleate; lupenone; or  
lupenon-1,2-ene-2-ol.

20 Specific values for the compounds of formula (II)  
are as follows.

A specific value for the bond between carbons 1 and  
2 is a single bond.

A specific value for  $R_1$  is -O-Y, wherein Y is  
25 hydrogen, an amino acid, or (C<sub>1</sub>-C<sub>6</sub>)alkyl; wherein any  
alkyl can be optionally substituted with one or more  
oxo, hydroxy, amino, phenyl, or carboxy any alkyl can be  
optionally interrupted with one or more oxy or thio; any  
phenyl can be optionally substituted with one or more  
30 hydroxy or carboxy.

Another specific value for  $R_1$  is -O-Y, wherein Y is hydrogen, 3-carboxypropanoyl, 4-carboxybutanoyl, or 2-amino-2-methylbutanoyl.

A specific value for  $R_2$  is hydrogen.

5 A specific value for  $R_3$  is hydrogen.

A specific value for  $R_4$  is methyl.

A specific value for  $R_5$  is methyl.

A specific value for  $R_6$  is hydrogen.

10 A specific value for the bond between carbons 12 and 13 is a single bond.

A specific value for  $R_7$  is hydrogen.

A specific value for  $R_8$  and  $R_{11}$  together is -O-CH<sub>2</sub>-.

A specific value for  $R_9$  is methyl.

A specific value for  $R_{10}$  is methyl.

15 A specific group of compounds of formula (II) is the compounds wherein  $R_1$  is -O-Y and Y is hydrogen, an amino acid, or (C<sub>1</sub>-C<sub>6</sub>)alkyl; wherein the alkyl of Y can be optionally substituted with one or more oxo, hydroxy, amino, carboxy, or phenyl optionally substituted with  
20 one or more hydroxy or carboxy; and can be optionally interrupted with one or more oxy or thio;  $R_2$  is hydrogen;  $R_3$  is hydrogen and the bond between carbons 1 and 2 is a single bond;  $R_4$  and  $R_5$  are each methyl;  $R_6$  is hydrogen and the bond between carbons 12 and 13 is a  
25 single bond;  $R_7$  is hydrogen;  $R_8$  and  $R_{11}$  together are -O-CH<sub>2</sub>-; and  $R_9$  and  $R_{10}$  are each methyl.

Another specific group of compounds of formula (II) is 3- $\beta$ -acetoxy-19 $\alpha$ H-19,28 lactone oleanan; allobetulin; allobetulin-3-succinate; allobetulin-3-glycine;  
30 allobetulin lactone; allobetulin lactone-3-acetate;

- allobetulin lactone-3-phosphate; allobetulin-3-L-alanine; allobetulin-3-L-valine; allobetulin-3-L-proline ester; allobetulin-3-succinate; allobetulin-3-diglycolate; allobetulin-3-phthalate; allobetulin-3-methylenamine; allobetulin-3-ethanolamine; allobetulin-3-glycolate; allobetulin-3-glutarate; allobetulin-28-glutarate; allobetulin-3-methylamine HCl; allobetulin-3-phosphate; allobetulin-3-(polyethylene glycol)-COOH (Mw=674); allobetulon; allobetulon lactone-1-ene-2-ol; allobetulon lactone-1-en-2-succinate; allobetulon-1-ene-2-ol; allobetulon-1-ene-2-diglycolate; 3-allobetulon-1-ene-2-succinate; allobetulin-3-(poly(ethylene glycol)bis(carboxymethyl ester)); or 3-allobetulon-1-ene-2-diglycolate.
- Another specific group of compounds of formula (II) is 3- $\beta$ -acetoxy-19 $\alpha$ H-19,28 lactone oleanan; allobetulin; allobetulin-3-succinate; allobetulin lactone; allobetulin lactone-3-acetate; allobetulin lactone-3-phosphate; allobetulin-3-L-valine; allobetulin-3-L-proline; allobetulin-3-succinate; allobetulin-3-diglycolate; allobetulin-3-methylenamine; allobetulin-3-ethanolamine; allobetulin-3-glycolate; allobetulin-3-glutarate; allobetulin-3-glutarate; allobetulin-3-(polyethylene glycol)-COOH (Mw=674); allobetulon; allobetulon lactone-1-ene-2-ol; allobetulon lactone-1-en-2-succinate; allobetulon-1-ene-2-ol; allobetulon-1-ene-2-diglycolate; 3-allobetulon-1-ene-2-succinate; or allobetulin-3-(poly(ethylene glycol)bis(carboxymethyl ester)).

Another specific group of compounds of formula (II) is allobetulin, allobetulin-3-glutarate, allobetulin-3-succinate, or allobetulin-3-L-valine.

In one specific embodiment of a compound of formula  
5 (IV),  $R_2$ ,  $R_5$ , and  $R_8$  are each independently absent, hydroxyl, N-diazabicyclo[2.2.2]octyl, N-pyridinium, N-alkyl-N-piperidino, N-alkyl-N-morpholino, N-azabicyclo[2.2.2]octyl, or  $NR_aR_bR_c$ ; provided at least one of  $R_2$ ,  $R_5$ , and  $R_8$  is  $N^+$ -containing heteroaryl,  $N^+$ -  
10 containing heterocycle, or  $-N^+R_aR_bR_c$ . In this embodiment N-diazabicyclo[2.2.2]octyl; N-pyridinium; N-alkyl-N-piperidino; N-alkyl-N-morpholino; and N-azabicyclo[2.2.2]octyl can optionally be substituted on one or more suitable carbon atoms with one or more oxo,  
15 hydroxy, mercapto, alkyl, hydroxyalkyl, halo, nitro, cyano,  $(C_1-C_6)$ alkoxy,  $-COOR_d$ , or  $-NR_dR_e$ . In this embodiment also, any alkyl or alkylene of  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_5$ ,  $R_7$ , or  $R_8$  can optionally be substituted with one or more oxo or  $-NR_dR_e$ , and optionally interrupted with one or  
20 more oxy, imino, or thio, and can optionally be partially unsaturated.

In another specific embodiment of a compound of formula (IV),  $R_1$  is absent and  $R_2$  is hydrogen, N-diazabicyclo[2.2.2]octyl, or N-dimethylamino-N-  
25 pyridinium.

In another specific embodiment of a compound of formula (IV),  $R_3$  and  $R_4$  are absent, and  $R_5$  is hydrogen.

In another specific embodiment of a compound of formula (IV),  $R_3$  is oxy;  $R_4$  is absent or  $(C_1-$   
30  $C_5)$ alkylenecarbonyl; and  $R_5$  is hydrogen, N-

diazabicyclo[2.2.2]octyl; 4-dimethylamino-N-pyridinium;  
 4-hydroxybutyl-N-diazabicyclo[2.2.2]octyl; 4-benzyl-N-  
 diazabicyclo[2.2.2]octyl; tetramethylethylenediamine-N-  
 yl; N'-benzyl-N,N,N',N'-tetramethylethylenediamine-N-yl;  
 5 N-pyridinium; 4-hydroxymethyl-N-pyridinium; 2,4-  
 dimethyl-N-pyridinium; 3,5-dimethyl-N-pyridinium;  
 octyldimethylammonium; or tetradecyldimethylammonium.

In another specific embodiment of a compound of  
 formula (IV), R<sub>6</sub> is oxy; R<sub>7</sub> is absent or (C<sub>1</sub>-  
 10 C<sub>5</sub>)alkylenecarbonyl; and R<sub>8</sub> is hydrogen, N-  
 diazabicyclo[2.2.2]octyl; 4-dimethylamino-N-pyridinium;  
 N'-(4-hydroxybutyl)-N-diazabicyclo[2.2.2]octyl; N'-  
 benzyl-N-diazabicyclo[2.2.2]octyl; N,N,N',N'-  
 tetramethylethylenediamine-N-yl; N'-benzyl-N,N,N',N'-  
 15 tetramethylethylenediamine-N-yl; N-pyridinium; 4-  
 hydroxymethyl-N-pyridinium; 2,4-dimethyl-N-pyridinium;  
 3,5-dimethyl-N-pyridinium; octyldimethylammonium;  
 tetradecyldimethylammonium; 2-methyl-N-pyridinium; 4-  
 hydroxy-N-methyl-N-piperidinium; or N-methyl-N-  
 20 morpholino.

In particular embodiments of the invention, the  
 compound of formula (IV) is:  
 lup-20(29)-ene-3,28-bis-(N-pyridiniumacetate);  
 lup-20(29)-ene-3-[N-(4-oxybutyl)-1,4-  
 25 diazabicyclo[2.2.2]octyl-N'-acetate];  
 lup-20(29)-ene-3,28-bis[N-(1,4-  
 diazabicyclo[2.2.2]octyl)acetate];  
 lup-20(29)-ene-3,28-bis[N-(N'-  
 benzyldiazabicyclo[2.2.2]octyl)acetate];



- lup-20(29)-ene-3,28-bis[N-(N'-(4-oxybutyl)diazabicyclo[2.2.2]octyl)acetate];
- lup-20(29)-ene-3-[N-(1,4-diazabicyclo[2.2.2]octyl)acetate];
- 5 lup-20(29)-ene-3,28-bis[(tetramethylethylenediamine-N-yl)acetate];
- lup-20(29)-ene-3,28-bis[N'-benzyl-N,N,N',N'-tetramethylethylenediamine-N-yl)acetate];
- lup-20(29)-ene-3-[N-(N'-(benzyl)diazabicyclo[2.2.2]octyl)acetate];
- 10 bis(N,N'-pyridinium-2-ethyl)lup-20(29)-ene-3,28-dicarbamate;
- 1-(3,28-(diacetoxylup-20(29)-ene-30-yl)-4-(dimethylamino)pyridinium;
- 15 lup-20(29)-ene-3,28-bis(N-pyridinium-2-propionate);
- lup-20(29)-ene-3,28-bis(N-pyridinium-3-propionate);
- lup-20(29)-ene-3,28-bis(N-pyridinium-4-butyrate);
- lup-20(29)-ene-3,28-bis(N-pyridinium-4-butyrate);
- lup-20(29)-ene-3,28-bis(N-pyridinium-2-butyrate);
- 20 1-[3,28-(diacetoxylup-20(29)-ene-30-yl)-1,4-diazabicyclo[2.2.2]octyl];
- 3,28-bis[3-(1-piperidinyl)propanoyloxy]lup-20(29)-ene;
- 1-(3,28-dihydroxylup-20(29)-ene-30-yl)-4-(dimethylamino)pyridinium;
- 25 lup-20(29)-ene-3,28-bis[N-(4-dimethylaminopyridinium)-2-propionate];
- lup-20(29)-ene-3,28-bis[N-(1,4-diazabicyclo[2.2.2]octyl)-2-propionate];
- 1-(lup-20(29)-ene-30-yl)-1,4-diazabicyclo[2.2.2]octane;
- 30 1-(3,28-dihydroxylup-20(29)-ene-30-yl)-pyridinium;

- lup-20(29)-ene-3,28-bis[N-(1,4-diazabicyclo[2.2.2]octyl)-4-butyrate];  
1-(3,28-dihydroxylup-20(29)-ene-30-yl)-[N-3-(hydroxymethyl)pyridinium];
- 5 1-(3,28-dihydroxylup-20(29)-ene-30-yl)-[N-(3,5-dimethylpyridinium)];  
bis[N-(1,4-diazabicyclo[2.2.2]octyl)-2-ethyl]-lup-20(29)-ene-3,28-dicarbamate;  
lup-20(29)-ene-3,28-bis[N-(3-oxymethylpyridinium)acetate];
- 10 lup-20(29)-ene-3,28-bis[N-(2-oxymethylpyridinium)acetate];  
lup-20(29)-ene-3,28-bis[N-(2-methylureapyridinium)acetate];
- 15 lup-20(29)-ene-3-[N-(2-oxymethylpyridinium)acetate];  
lup-20(29)-ene-3,28-bis[N-(N-methylmorpholino)acetate];  
lup-20(29)-ene-3,28-bis[N-(4-hydroxyl-N-methylpiperidino)acetate];  
lup-20(29)-ene-3-[N-(3-ureamethylpyridinium)acetate];
- 20 lup-20(29)-ene-3-(N-pyridiniumacetate);  
lup-20(29)-ene-3,28-bis[N-(1,4-diazabicyclo[2.2.2]octyl)-2-butyrate];  
lup-20(29)-ene-3,28-bis[N-(4-dimethylpyridinium)-2-butyrate];
- 25 lup-20(29)-ene-3,28-bis[N-(4-dimethylaminopyridinium)-4-butyrate];  
lup-20(29)-ene-3,28-bis[N-(4-dimethylaminopyridinium)-3-propionate];  
1-(3,28-dihydroxylup-20(29)-ene-30-yl)-4-
- 30 (hydroxymethyl)pyridinium;

- 1- (3,28-dihydroxylup-20(29)-ene-30-yl)-3-hydroxy-1-azabicyclo[2.2.2]octane;  
 lup-20(29)-ene-3,28-bis[N-(2,4-dimethylpyridinium)acetate];  
 5 lup-20(29)-ene-3,28-bis[N-(3,5-dimethylpyridinium)acetate];  
 lup-20(29)-ene-3,28-bis[N-(4-dimethylaminopyridinium)acetate];  
 lup-20(29)-ene-3-[N-(2-methylpyridinium)acetate];  
 10 lup-20(29)-ene-3-[N-(2,4-dimethylpyridinium)acetate];  
 lup-20(29)-ene-3-[N-(4-hydroxy-N-methylpiperidino)acetate];  
 lup-20(29)-ene-3-[N-(N-methylmorpholino)acetate];  
 lup-20(29)-ene-3-[N-(3,5-dimethylpyridinium)acetate];  
 15 lup-20(29)-ene-3-[N-(4-dimethylaminopyridinium)acetate];  
 lup-20(29)-ene-3,28-bis(octyldimethylammoniumacetate);  
 lup-20(29)-ene-3-octyldimethylammoniumacetate;  
 lup-20(29)-ene-3,28-bis(tetradecyldimethylammoniumacetate);  
 20 lup-20(29)-ene-3-tetradecyldimethylammoniumacetate;  
 N,N,N',N'-tetramethylethylenediamine-N,N'-bis-[lup-20(29)-ene-3-acetate];  
 1-[(lup-20(29)-en-3 $\beta$ -yl)oxycarbonylmethyl]-4-aza-1-azonia-bicyclo[2.2.2]octane;  
 25 1-[(lup-20(29)-en-3 $\beta$ -yl)oxycarbonylmethyl]trimethylammonium; or  
 1-[(lup-20(29)-en-3 $\beta$ -yl)oxycarbonylmethyl]pyridinium.

A specific embodiment of the compound of formula (VI) is the compound wherein R<sub>1</sub> is hydrogen, alkyl, or

hydroxyalkyl;  $R_2$  is oxymethylene, thiomethylene, iminomethylene, or methylene;  $R_3$  and  $R_6$  are each independently absent or alkylencarbonyl;  $R_4$  and  $R_7$  are each independently hydrogen, N-diazabicyclo[2.2.2]octyl; 5 N-pyridinium; N-alkyl-N-piperidino; N-alkyl-N-morpholino; N-azabicyclo[2.2.2]octyl; or  $NR_aR_bR_c$ ; or  $R_1$ ,  $R_2$ ,  $R_3$ , and  $R_4$  are together  $-O-CH_2-$ . In this case, N-diazabicyclo[2.2.2]octyl; N-pyridinium; N-alkyl-N-piperidino; N-alkyl-N-morpholino; and N- 10 azabicyclo[2.2.2]octyl can optionally be substituted on carbon with one or more alkyl, hydroxyalkyl, hydroxy,  $COOR_d$ , or  $NR_dR_e$ .  $R_a$ ,  $R_b$ , and  $R_c$  are each independently aryl or  $(C_1-C_{24})$ alkyl; wherein  $R_d$  and  $R_e$  are each independently hydrogen or alkyl. Any alkylene or alkyl 15 can optionally be substituted on carbon with one or more oxo, hydroxy, halo, nitro, cyano, trifluoromethyl,  $COOR_d$ , or  $-NR_dR_e$ , and optionally interrupted with one or more oxy, imino, or thio, and where any alkyl or alkylene can optionally be partially unsaturated.

20 Another specific embodiment of the compound of formula (VI) is the compound wherein  $R_1$ ,  $R_2$ ,  $R_3$ , and  $R_4$  are together  $-O-CH_2-$ .

Another specific embodiment of the compound of formula (VI) is the compound wherein  $R_5$  is oxy.

25 Another specific embodiment of the compound of formula (VI) is the compound wherein  $R_6$  is acetyl.

Another specific embodiment of the compound of formula (VI) is the compound wherein  $R_7$  is N-diazabicyclo[2.2.2]octyl; N-pyridinium; or  $-N^+(CH_3)_3$ .

In particular embodiments of the invention, the compound of formula (VI) is:

1-[(19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan-3 $\beta$ -yl)oxycarbonylmethyl]-4-aza-1-azonia-bicyclo[2.2.2]octane;

- 5 [(19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan-3 $\beta$ -yl)oxycarbonylmethyl]trimethylammonium; or  
1-[(19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan-3 $\beta$ -yl)oxycarbonylmethyl]pyridinium.

- A specific class of triterpene compounds present in the compositions of the instant invention include:
- Betulin; Lupeol; Lupeol acetate; Lupenone; 2-hydroxy-olean-1,2-ene-3-one-28,19-lactone; Allobetulinlactone; Allobetulonlactone; Allobetulinlactone trifluoroacetate; Allobetulinlactone phosphodichloride; 2-brom-
- 15 Allobetulinlactone; Allobetulinlactone phosphate; Allobetulinlactone acetate; Allobetulin; Allobetulon; Allobetulin trifluoroacetate; Allobetulin phosphodichloride; Allobetulin phosphate; Allobetulin acetate; Allobetulon -1-ene-2-ol; 2-Br-Allobetulin; 3-
- 20 TMS-O-Allobetulin; 3-aminomethyl-3hydroxy- Allobetulin; Allobetulon cyanohydrin; Allobetulin 3-tosylate; Betulon 28-acetate; Betulin 28-acetate; Betulonic aldehyde; Betulin dimesylate; Betulin-3-O-acetate-28-trifluoroacetate; Betulon; 3-O-acetyl-Betulinic
- 25 aldehyde; Betulinic aldehyde; Betulon-1-ene-2-ol; Betulin ditrifluoroacetate; Betulin -28- tosylate; Betulin ditosylate; Betulinic acid; Betulonic acid; 3-O-acetyl-Betulinic acid; Betulin caffeate; Betulin dioxalyl chloride; Betulindiamine; Betulin 3-amine;

Betulin 28-amine; Betulindihydroxyme;  
 Betulindiphosphate; Betulindiphosphodichloride;  
 Betulindiphosphate sodium salt; Betulin 3,28-bis((1R)-  
 trans-chrysanthemate); Betulin 28-(1R)-trans-  
 5 chrysanthemate; Betulin bis(N-pyridyl-2-acetate)  
 dichloride; Betulin 3,28-diacrylate; Betulin 3,28-  
 dimethacrylate; Betulin 28-acrylate-3-formiate; Betulin-  
 28-monomethacrylate; Betulin-3,28-bis(P,P'-  
 triphenylphosphinoacetate); Betuline-3,28-  
 10 bis(tetramethylenediamino acetate); Betuline-3,28-  
 bis(N,N'-diazabicyclo[2.2.2]octanoacetate); Betulin-  
 3,28-bis(N,N'-dibenzylidiazabicyclo[2.2.2]octanoacetate);  
 Betulin-3,28-bis(N,N'-(4-  
 oxybutyl)diazabicyclo[2.2.2]octanoacetate); Betulin-  
 15 3,28-bis(oxyacetate); 3,28-Di(methylthiomethylene)  
 betulin; 3-Methylthiomethyleneallobetulin; 28-  
 Methylthiomethylenebetuline 3-acetate; 28-  
 Methylthiomethylenebetul-3-one; Betulin 3-acetate-28-  
 mesylate; Betulin 3,28-di(trifluoroacetamidglycinate);  
 20 Betulin 28-trifluoroacetamidglycinate; Betulin 3,28-  
 diacetylsalicylate; Betulin 3,28-di(2-  
 oxyethylenoxyoxalate); Allobetulin 3-(poly(ethylene  
 glycol)bis(carboxymethyl)ether)ester; Allobetulin 3-  
 (poly(ethylene glycol)bis(carboxymethyl)ether)methyl  
 25 ester; Betulin 3,28-di(poly(ethylene  
 glycol)bis(carboxymethyl)ether)ester; Betulin 3,28-  
 di(poly(ethylene glycol)bis(carboxymethyl)ether)ester;  
 Betulin 3,28-di(poly(ethylene  
 glycol)bis(carboxymethyl)ether)methyl ester;  
 30 Poly(ethylene glycol)bis(carboxymethyl)ether 28,28'

dibetuline ester; Betulin 3,28-di(ethyl) carbamate;  
 Betulin 3,28-disuccinate; Betulin 28-succinate; Betulin  
 3,28-disuccinyl dipoly(ethylene glycol)ester; 28,28'-  
 Dibetulin poly(propylene glycol) toluene-2,4-dicarbamate  
 5 terminated; Mixture of suberinic acids; cis-9,10-epoxy-  
 18-hydroxyoctadecanoic acid; cis-9,10-epoxy-18-  
 hydroxyoctadecanoic acid; cis-9,10-epoxy-18-  
 hydroxyoctadecanoic acid + polyethyleneimine; cis-9,10-  
 epoxy-18-hydroxyoctadecanoic acid + polyethyleneimine;  
 10 cis-9,10-epoxy-18-hydroxyoctadecanoic acid +  
 polyethyleneimine; 22-hydroxydocosanoic acid +  
 polyethyleneimine; Dicarboxylic acids fraction +  
 polyethyleneimine; Potassium salt of cis-9,10-epoxy-18-  
 hydroxyoctadecanoic acid; 22-hydroxydocosanoic acid +  
 15 polyethyleneimine; Docosandioic acid, 85% +  
 polyethyleneimine; Lupeol 3-(polyethyleneimine  
 propionate); cis-9,10-epoxy-18-hydroxyoctadecanoic acid  
 + polyethyleneimine; Betulin 3,28-disuccinate +  
 polyethyleneimine; Betulin 3,28-disuccinate +  
 20 polyethyleneimine; Betulin 3,28-disuccinyl  
 polyethyleneimine amide; Betulin 3,28-disuccinyl  
 polyethyleneimine amide; Betulin 3,28-disuccinyl  
 dichloride; Betulin 3,28-disuccinyl (1-  
 methylpyrazine)amide; Lupeol 3-acrylate; cis-9,10-epoxy-  
 25 18-acetoxyoctadecanoic acid; cis-9,10-epoxy-18-(*m*-  
*nitrobenzoyloxy*)octadecanoic acid; cis-9,10-epoxy-18-  
 acetoxyoctadecanoic acid (R) -(+)- $\alpha$ -phenylethylamide;  
 cis-9,10-epoxy-18-(*m*-*nitrobenzoyloxy*)octadecanoic acid  
 (R) -(+)- $\alpha$ -phenylethylamide; cis-9,10-epoxy-18-

hydroxyoctadecanoic acid (1) + polyethyleneimine; *cis*-  
 9,10-epoxy-18-(3-acetoxylithocholioxo)octadecanoic acid  
 methyl ester; Betulin 3,28-dimaleate + polyethylenimine;  
 Betulin 3,28-dimaleate disodium salt; Betulin 3,28-  
 5 dimaleate; 9,10,18-trihydroxyoctadecanoic acid; *cis*-  
 9,10-epoxy-18-hydroxyoctadecanoic acid +  
 polyethyleneimine; Betulin 3,28-diacetate; Betulin 3-  
 acetate; Betulin 3,28-dibenzoate; Betulin 3-benzoate;  
 Betulinic acid methyl ester; Betulin 3,28-di(2'-  
 10 chloropropionate); Betulin 3,28-di(3'-chloropropionate);  
 Betulin 3,28-di(4'-chlorobutyrate); bis(N,N'-pyridino-2-  
 ethyl) betulin-3,28-carbamate dichloride; Betulin 3,28-  
 di(4'-bromobutyrate); Betulin 3,28-di(2'-bromobutyrate);  
 Betulin-3,28-bis(2-thiuroniumacetate) dihydrochloride;  
 15 Betulin - 3,28 - bis (N,N'-pyridino-3-propionate)  
 dichloride; Betulin - 3,28 - bis (N,N'-pyridino-2-  
 propionate) dichloride; Betulin - 3,28 - bis (N,N'-  
 pyridino-4-butyrate) dibromide; Betulin - 3,28 - bis  
 (N,N'-pyridino-4-butyrate) dichloride; Betulin - 3,28 -  
 20 bis (N,N'-pyridino-2-butyrate) dibromide; 1-(3,28-  
 diacetoxylup-20-en-30-yl)-4-(dimethylamino) pyridinium  
 bromide; Betulin-3-(N-DABCO-2-acetate); Betulin-3-  
 chloroacetate; Betulin-3(N-benzyl-N'-DABCO-2-acetate);  
 Betulin-3-(N'-oxybutyl-N-DABCO-2-acetate); *Mixture of*  
 25 *betulin-3-phosphonoacetate and betulin-28-*  
*phosphonoacetate*; Dihydro-29-carboxy-betulin;  
 Dimethylamide dihydro-29-carboxybetulin; Betulin 3,28-  
 disuccinyl di(4-methyl-4-benzylpyrazonium bromide)  
 amide; 9,10,18-treo-trihydroxyoctadecanoic acid  
 30 (Phloionolic acid); 22-Hydroxydocosanoic acid (IK32);



Birch bark tannin; Birch bark tannin -Na salt; Birch bark tannin -K salt; Betulin-3,28-bis(benzyltetramethyl-ethylenediamino acetate chloride); Betuline-3,28-dioxalate; Betulin-28-maleate; Betulin-3,28-  
5 bis(diacetyltartrate); Betulin-3,28-bis(diacetyltartrate) disodium salt; N-(3,28-diacetoxylup-20-en-30-yl)-1,4-diazabicyclo[2.2.2]octane bromide; 3,28,30-triacetoxylup-20(29)-ene; 3,28-bis(3-(1-piperidinyl)propanoyloxy)lup-20(29)-ene  
10 dihydrochloride; 30-Bromo-3,28-dihydroxylup-20(29)-ene; 1-(3,28-dihydroxylup-20(29)-en-30-yl)-4-(dimethylamino)pyridinium bromide; 1-(lup-20(29)-en-30-yl)-1,4-diazabicyclo[2.2.2]octane bromide; S-(3,28-dihydroxylup-20(29)-en-30-yl)thiuronium bromide; 1-  
15 (3,28-dihydroxylup-20(29)-en-30-yl)-pyridinium bromide; 1-(3,28-dihydroxylup-20(29)-en-30-yl)-3,5-dimethylpyridinium bromide; Adduct of 1 mole of betulin-3-chloroacetate and 1 mole of SV-23; betulin-3,28-bis(2-thiuroniumacetate) dihydrochloride; lup-20(29)-ene-3,28-  
20 bis(N,N'-4-dimethylaminopyridino-2-propionate) dichloride; lup-20(29)-ene-3,28-bis(N,N'-1,4-diazabicyclo[2.2.2]octane-2-propionate) dichloride; lup-20(29)-ene-3,28-bis(thiuronium-4-butirate) dichloride; 1-(3,28-dihydroxylup-20(29)-en-30-yl)-4-  
25 (hydroxymethyl)pyridinium bromide; 1-(3,28-dihydroxylup-20(29)-en-30-yl)-3-hydroxy-1-azabicyclo[2.2.2]octane bromide; 3,28-dihydroxy-30-(1,2,4-triazol-1-yl)-lup-20(29)-ene; 22-hydroxydocosanoic acid sodium salt; 22-hydroxydocosanoic acid potassium salt; 9,10,18-  
30 trihydroxyoctadecanoic acid sodium salt; 9,10,18-

trihydroxyoctadecanoic acid potassium salt; 9,10-epoxy-  
 18-hydroxyoctadecanoic acid sodium salt; 9,10-epoxy-18-  
 hydroxyoctadecanoic acid potassium salt; lup-20(29)-ene-  
 3,28-bis(N,N'-1,4-diazabicyclo[2.2.2]octane-4-butyrate)  
 5 dibromide; lup-20(29)-ene-3,28-bis(N,N'-1,4-  
 diazabicyclo[2.2.2]octane-4-butyrate) dichloride;  
 Bis(N,N'-1,4-diazabicyclo[2.2.2]octane-2-ethyl)-lup-  
 20(29)-ene-3,28-carbamate dichloride; 30-Bromo-3,28-  
 bis(chloroacetyl)lup-20(29)-ene; 1-(3,28-diacetoxylup-  
 10 20(29)-en-30-yl)-pyridinium bromide; 1-(3,28-  
 dihydroxylup-20(29)-en-30-yl)-3-  
 (hydroxymethyl)pyridinium bromide; lup-20(29)-en-3,28-  
 bis(pyridylmethylurea acetate) dichloride; lup-20(29)-  
 en-3,28-bis(3-oxymethylpyredyniumacetoxyl) dichloride;  
 15 lup-20(29)-en-3,28-bis(2-oxymethylpyredyniumacetoxyl)  
 dichloride; lup20(29)-ene- 3,28 - bis (N,N'-4-  
 dimethylaminopyridino-3-propionate) dichloride;  
 lup20(29)-ene - 3,28 - bis (N,N'-4-  
 dimethylaminopyridino-4-butyrate) dibromide; lup20(29)-  
 20 ene - 3,28 - bis (N,N'-4-dimethylaminopyridino-2-  
 butyrate) dibromide; lup-20(29)-ene-3,28-bis(N,N'-1,4-  
 diazabicyclo[2.2.2]octane-2-butyrate) dibromide; betulin  
 3-mono(N-pyridylacetate) chloride; lup-20(29)-en-3 mono  
 (2-oxymethylpyredyniumacetoxyl) chloride; Betulin 3, 28-  
 25 bis(chloroacetate) dichloride + 4-Hydroxy-1-  
 methylpiperidine; Betulin 3,28 bis (chloroacetate)  
 dichloride + 4-methylmorpholine; lup-20(29)-en-3  
 mono(pyridylmethylurea acetate) chloride; 3,28,30-  
 Trihydroxylup-20(29)-ene; Lup20(29)-ene- 3,28 - bis  
 30 (2,4-lutidine-1-acetate) dichloride; lup20(29)-ene- 3,28

- bis (3,5-lutidine-1-acetate) dichloride; lup20(29)-ene- 3,28 - bis (4-(dimethylamino)-1-(acetate) pyridine) dichloride; lup20(29)-ene- 3- (2-Picoline-1-acetate) chloride; lup20(29)-ene- 3-mono (2,4-lutidine-1-acetate) chloride; lup20(29)-ene- 3 (4-hydroxy-1-Methyl,1-acetate piperidine) chloride; lup20(29)-ene- 3 (4'-Methylmorpholine-1'-acetate) chloride; lup20(29)-ene- 3 (3,5-lutidine-1-acetate) chloride; lup20(29)-ene- 3(4-(dimethylamino)-1-(acetate) pyridine) chloride; Betulin

10 3,28 bis(octhyldimethylamoniumacetoxyl)dichloride; Betulin 3(octhyldimethylamoniumacetoxyl)chloride; Betulin 3,28 bis(tetradecyldimethylamoniumacetoxyl)dichloride; Betulin 3 (tetradecyldimethylamoniumacetoxyl) chloride; 3,28-

15 dihydroxy-30-(imidazol-1-yl)-lup-20(29)-ene; 3,28-diacetoxyl-30-(triazol-1-yl)-lup-20(29)-ene; Betulin-3-(2-chloropropionate); Betulin-3-(N-1-triazolylacetate); Betulin-3-(N-1-triazolyl)-2-propionate; Betulin-3,28-bis(bromoacetate); 3-Acetoxylup-20(29)-ene-28-aldoxyme;

20 3-Acetoxylup-20(29)-ene-28-alldmethoxyme; Lup-20(29)-ene-3-one-28-al dioxyme; Lup-20(29)-ene-3-one-28-al dimethoxyme; 3-(1,2,4-Triazol-1-yl)acetylallobetulin; 3-(2-(1,2,4-Triazol-1-yl)propionyl)allobetulin; Lup-20(29)-ene-3-acetate-28-p-nitrobenzoate; Lup-20(29)-ene-

25 3-acetate-28-o-nitrobenzoate; Lup-20(29)-ene-3-acetate-28-m-nitrobenzoate; Betulin-3-(N-1-pyrazolyl)-2-propionate; 3,28-bis(2-(triazol-1-yl)propionate)betulin; 28-(2-Chloropropionyl)betulin; 28-(2-(triazol-1-yl)propionyl)betulin; 3,28-bis(2-(imidazol-1-

30 yl)propionyl)betulin; 3,28-Dimethylbetulin;


3-((Imidazol-1-yl)acetoxy)-19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan; 3-  
 [2-(Imidazol-1-yl)propionyloxy]-19 $\beta$ ,28-epoxy-18 $\alpha$ -  
 oleanan; 3-((Pyrazol-1-yl)acetoxy)-19 $\beta$ ,28-epoxy-18 $\alpha$ -  
 oleanan; 3-[2-(Pyrazol-1-yl)propionyloxy]-19 $\beta$ ,28-epoxy-  
 5 18 $\alpha$ -oleanan; 28-(2-imidazolylpropionyloxy)lup-20(29)-  
 ene; 1-(3,28-dihydroxylup-20(29)-en-30-yl)piperidine; 1-  
 (3,28-diacetoxylup-20(29)-en-30-yl)piperidine; 3,28,30-  
 tris(chloroacetoxy)lup-20(29)-ene; 3 $\beta$ -(N-  
 diazabicyclo[2.2.2]octylacetyloxy)-19 $\beta$ ,28-epoxy-18 $\alpha$ -  
 10 oleanan bromide; 3 $\beta$ -(N-  
 diazabicyclo[2.2.2]octylacetyloxy)-19 $\beta$ ,28-epoxy-18 $\alpha$ -  
 oleanan chloride; 3 $\beta$ -(N-pyridiniumacetyloxy)-19 $\beta$ ,28-  
 epoxy-18 $\alpha$ -oleanan bromide; 3 $\beta$ -(N-pyridiniumacetyloxy)-  
 19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan chloride; 3 $\beta$ -[-(N',N'-  
 15 dimethylaminopyridinium)-N-acetyloxy]-19 $\beta$ ,28-epoxy-18 $\alpha$ -  
 oleanan bromide; 3 $\beta$ -[-(N',N'-dimethylaminopyridinium)-N-  
 acetyloxy]-19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan chloride; 3 $\beta$ -(N-  
 octyldimethylaminoacetyloxy)-19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan  
 bromide; 3 $\beta$ -[N-(2-hydroxyethyl)laminoacetyloxy]-19 $\beta$ ,28-  
 20 epoxy-18 $\alpha$ -oleanan bromide; 3 $\beta$ -[N,N-dimethyl-N-(2-  
 hydroxyethyl)aminoacetyloxy]-19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan  
 bromide; 3 $\beta$ -[N,N-dimethyl-N-(2-  
 hydroxyethyl)aminoacetyloxy]-19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan  
 chloride; 3 $\beta$ -[N-(3-hydroxymethylpyridinium)acetyloxy]-  
 25 19 $\beta$ ,28-epoxy-18 $\alpha$ -oleanan bromide; 3 $\beta$ -[(N,N,N',N'-  
 'tetramethylethylenediamino)acetyloxy]-19 $\beta$ ,28-epoxy-18 $\alpha$ -

oleanan bromide; 3,28-dimethoxy-30-bromobetulin;  
combinations thereof; and pharmaceutically acceptable  
salts thereof.


The compounds present in the compositions of the  
5 instant invention can comprise one triterpene moiety  
derivatized with one or more quaternary ammonium group  
(e.g., N<sup>+</sup>-containing group). Preferred N<sup>+</sup>-containing  
groups include N<sup>+</sup>-containing heteraryl, N<sup>+</sup>-containing  
heterocycle, or -NR<sub>a</sub>R<sub>b</sub>R<sub>c</sub>, wherein R<sub>a</sub>, R<sub>b</sub>, and R<sub>c</sub> are each  
10 independently (C<sub>1</sub>-C<sub>24</sub>)alkyl, aryl, arylalkyl,  
heteroarylalkyl, heterocycle, or heterocyclealkyl.  
Preferably, a single triterpene moiety is derivatized  
with one, two, three, or four N<sup>+</sup>-containing groups.

The compounds present in the compositions of the  
15 instant invention can also comprise more than one  
triterpene moiety derivatized to a single N<sup>+</sup>-containing  
group and comprise oligomers of alternating triterpene  
moieties and N<sup>+</sup>-containing groups. In these cases, the  
triterpene moieties can be further derivatized with  
20 additional N<sup>+</sup>-containing groups.

For instance, one embodiment of the invention  
provides a composition that includes a compound of  
formula (VII) or (VIII):



(VII)



(VIII)

Each  $R_1$  is independently  $(C_1-C_{24})$ alkyl or is alkylcarbonyl attached through the carbonyl to the oxy at the 3 or 28 carbon of betutlin, lupeol, or  
5 allobetulin, or to an imino or thio in place of the oxy at the 3 or 28 carbon of betulin, lupeol, or allobetulin, wherein if it is attached to an oxy, imino, or thio at the 28 carbon of allobetulin, carbon 19 is a methylene.  $R_2$  is  $(C_1-C_{24})$ alkyl.  $R_3$  is absent or  $(C_1-$   
10  $C_{24})$ alkyl or is alkylcarbonyl attached through the carbonyl to the oxy at the 3 or 28 carbon of betulin, lupeol, or allobetulin, or to an imino or thio in place of the oxy at the 3 or 28 carbon of betulin, lupeol, or allobetulin, wherein if it is attached to an oxy, imino,  
15 or thio at the 28 carbon of allobetulin, carbon 19 is a methylene. Any alkyl or alkylcarbonyl can optionally be substituted with one or more oxo, hydroxy, mercapto, or  $NR_dR_e$ .  $R_d$  and  $R_e$  are each independently hydrogen or alkyl. The compound in this case comprises at least two  
20 moieties selected from the group of betulin, allobetulin, and lupeol.

In one specific embodiment of the compound of formula (VIII), the compound is  $N,N,N',N'$ -tetramethylethylenediamine- $N,N'$ -bis-[lup-20(29)-ene-3-  
25 acetate].

In one embodiment, the compounds present in the compositions of the instant invention include one or more triterpene moieties covalently attached via a linker to a quaternary ammonium salt. The linker can  
30 attach to the triterpene moiety at any suitable position

of the triterpene. The linker can attach to the quaternary ammonium salt at the N<sup>+</sup> atom or at any other suitable position. The linker can be, for instance, alkylene, alkylcarbonyl, alkoxy, alkylimino, oxyalkylcarbonyl, carbonylalkylcarbonyl, or carbonylalkyloxy.

The quaternary ammonium salt can also be attached directly to the triterpene without a linker. The attachment in this case can be at any suitable position of the triterpene and any suitable position of the quaternary ammonium salt.

A specific method of the invention is the method of treating a mammal afflicted with a fungal infection comprising administering to the mammal a composition that includes an essential oil and an effective anti-fungal amount of a compound of formula (I)-(VI), wherein the mammal is a human.

Another specific method of the invention is the method of treating a mammal afflicted with a fungal infection comprising administering to the mammal a composition that includes an essential oil and an effective anti-fungal amount of a compound of formula (I)-(VI), wherein the fungal infection is caused by a dermatophytic fungus.

Another specific method of the invention is the method of treating a mammal afflicted with a fungal infection comprising administering to the mammal a composition that includes an essential oil and an effective anti-fungal amount of a compound of formula (I)-(VI), wherein the fungal infection is caused by a

dermatophytic fungus that is *Microsporum canis*,  
*Microsporum gyseum*, *Microsporum audouinii*, *Trichophyton*  
*tonsurans*, *Trichophyton mentagrophytes*, *Epidermophyton*  
*floccosum*, *Trichophyton rubrum*, or *Pityrosporum ovale*.

5 Another specific method of the invention is the  
method of treating a mammal afflicted with a fungal  
infection comprising administering to the mammal a  
composition that includes an essential oil and an  
effective anti-fungal amount of a compound of formula  
10 (I)-(VI), wherein the fungal infection is caused by  
*Candida albicans* or *Candida guilliermoundi*.

Another specific method of the invention is the  
method of treating a mammal afflicted with a fungal  
infection comprising administering to the mammal a  
15 composition that includes an essential oil and an  
effective anti-fungal amount of a compound of formula  
(I)-(VI), wherein the fungal infection is caused by  
*Blastomyces dermatidis* or *Cryptococcus neoformans*.

Another specific method of the invention is the  
20 method of inhibiting or killing a fungus comprising  
contacting the fungus or yeast with a composition that  
includes an essential oil and an effective anti-fungal  
amount of a compound of formula (I)-(VI), wherein the  
fungus is a dermatophytic fungus.

25 Another specific method of the invention is the  
method of inhibiting or killing a fungus comprising  
contacting the fungus with an effective anti-fungal  
amount of a composition that includes an essential oil  
and an effective anti-fungal amount of a compound of  
30 formula (I)-(VI), wherein the fungus is a dermatophytic



fungus that is *Microsporum canis*, *Microsporum gyseum*,  
*Microsporum audouinii*, *Trichophyton tonsurans*,  
*Trichophyton mentagrophytes*, *Epidermophyton floccosum*,  
*Trichophyton rubrum*, or *Pityrosporum ovale*.

5        Another specific method of the invention is the  
method of inhibiting or killing a fungus comprising  
contacting the fungus with an effective anti-fungal  
amount of a composition that includes an essential oil  
and an effective anti-fungal amount of a compound of  
10 formula (I)-(VI), wherein the fungus is *Candida albicans*  
or *Candida guilliermoundi*.

Another specific method of the invention is the  
method of inhibiting or killing a fungus comprising  
contacting the fungus with an effective anti-fungal  
15 amount of a composition that includes an essential oil  
and an effective anti-fungal amount of a compound of  
formula (I)-(VI), wherein the fungus is *Blastomyces*  
*dermatidis* or *Cryptococcus neoformans*.

Processes for preparing the triterpenes employed in  
20 the invention (i.e., compounds of formula (I)-(VI)) are  
provided as further embodiments of the invention and are  
illustrated by the following procedures in which the  
meanings of the generic radicals are as given above  
unless otherwise qualified. Specifically, the compounds  
25 of formula (I)-(VI) can be prepared from convenient  
starting materials, employing procedures (e.g., reagents  
and reaction conditions) known to those of skill in the  
art. For example, suitable reagents and reaction  
conditions are disclosed, e.g., in *Advanced Organic*  
30 *Chemistry, Part B: Reactions and Synthesis, Second*

Edition, Carey and Sundberg (1983); *Advanced Organic Chemistry, Reactions, Mechanisms, and Structure*, Second Edition, March (1977); Greene, T.W., *Protecting Groups In Organic Synthesis*, Third Edition, 1999, New York, John Wiley & sons, Inc.; and *Comprehensive Organic Transformations*, Second Edition, Larock (1999).

In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate,  $\alpha$ -ketoglutarate, and  $\alpha$ -glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

The compositions that include an essential oil and a compound of formula (I)-(VI) can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of

forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.

Thus, the present compositions can be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the compositions may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such preparations should contain at least 0.1% of the triterpene compound. The percentage of the compositions can, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound (i.e., triterpene compound) in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil

of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound (i.e., triterpene), sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound (i.e., triterpene) may be incorporated into sustained-release preparations and devices.

The composition may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the triterpene and essential oil can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising

the active ingredient, which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the triterpene and essential oil in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of

sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the triterpene and essential oil, plus any additional desired ingredient present in the previously sterile-filtered solutions.

For topical administration, the present compositions may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the triterpene and essential oil can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes,

gels, ointments, soaps, and the like, for application directly to the skin of the user.

Examples of useful dermatological compositions which can be used to deliver the compositions of the triterpene and essential oil, to the skin, are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

Useful dosages of the compositions of the triterpene and essential oil can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

Generally, the concentration of the compositions of the triterpene and essential oil in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.

The amount of the triterpene, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the  
5 recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.

The composition is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg,  
10 conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of triterpene per unit dosage form.

Ideally, the composition should be administered to achieve peak plasma concentrations of the triterpene of from about 0.5 to about 75  $\mu$ M, preferably, about 1 to 50  
15  $\mu$ M, most preferably, about 2 to about 30  $\mu$ M. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the triterpene, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the triterpene. Desirable blood  
20 levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the triterpene(s).

The desired dose may conveniently be presented in a  
25 single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations



from an insufflator or by application of a plurality of drops into the eye.

The ability of a composition of the invention to act as an anti-fungal agent may be determined using  
5 pharmacological models which are well known to the art.

The compositions of the invention may be also be useful as pharmacological tools for the further investigation of the mechanism of their anti-fungal action.

10 The compositions of the invention can also be administered in combination with other therapeutic agents that are effective to treat fungal infections, or to inhibit or kill a fungus.

The system used to name the triterpenes employed in  
15 the compositions of the invention will be clear to one of skill in the art based on the following examples. Names generally consist of the base structure, e.g., betulin, allobetulin, or lupeol, followed by a substituent. For example, betulin-28-succinate consists  
20 of a succinic acid molecule esterified to the hydroxyl at carbon 28 of betulin. If no number is given for the substituent, the substituent is attached to the hydroxyl at carbon 3 on the base structure.

Betulin-3-glycerol oxalate is a compound of formula  
25 (I), wherein  $R_4$  and  $R_5$  together are hydroxyl,  $R_2$  and  $R_3$  together are  $-\text{OC}(=\text{O})\text{C}(=\text{O})\text{OCH}_2\text{CH}(\text{OH})\text{CH}_2\text{OH}$ , and  $R_1$  is hydrogen. Betulin-1-ene-2-ol is a compound of formula (I), wherein the bond between carbons 1 and 2 is a double bond,  $R_1$  is hydroxyl,  $R_2$  and  $R_3$  together are  
30 hydroxymethyl, and  $R_4$  and  $R_5$  together are oxo. Uvaol is

a compound of formula (II), wherein R<sub>10</sub> is methyl, R<sub>9</sub> is hydrogen, R<sub>8</sub> is methyl, R<sub>7</sub> is hydrogen, R<sub>11</sub> is hydroxymethyl, R<sub>6</sub> is absent and the bond between carbons 12 and 13 is double, R<sub>3</sub> is hydrogen, R<sub>4</sub> and R<sub>5</sub> are methyl, R<sub>2</sub> is hydrogen, and R<sub>1</sub> is hydroxy. Oleanolic acid has the same structure as uvaol, except it has a carboxy at R<sub>11</sub> instead of hydroxymethyl. The structure of hederin hydrate is disclosed at page 871 of the Aldrich Chemical Co. 2000-2001 catalog. The structure of other named compounds can be found in standard sources such as the *Merck Index*. "Betulin arabinose galactan" refers to betulin in a solution of arabinogalactan.

Unless otherwise stated, amino acid substituents are attached to the compounds of the invention through their carboxyl groups via ester linkages. Thus, betulin-3,28-diglycine is the same compound as betulin-3,28-diglycine ester.

The compositions of the present invention can further optionally include an anti-infective agent. Suitable anti-infective agents include, for example:

[1R-(1R\*, 3S\*, 5R\*, 6R\*, 9R\*, 11R\*, 15S\*, 16R\*, 17R\*, 18S\*, 19E, 21E, 23E, 25E, 27E, 29E, 31E, 33R\*, 35S\*, 36R\*, 37S\*)]-33-[(3-Amino-3,6-dideoxy- $\beta$ -D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid (Amphotericin B);  
5-fluorocytosine (Flucytosine);

- 2,4-difluoro- $\alpha$ , $\alpha^1$ -bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol) (Fluconazole);
- griseofulvin microsize (Griseofulvin);
- (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride) (Terbinafine);
- 5 cis-1-acetyl-4-[4-[(2-(2,4-dichlorophenyl)-2-(1H-imadazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxyl]phenyl] piperazine (Ketoconazole);
- ( $\pm$ )-1-[(R\*)-sec-butyl]-4-[p-[4-[p-[(2R\*,4S\*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]- $\Delta^2$ -1,2,4-triazolin-5-one mixture
- 10 with ( $\pm$ )-1-[(R\*)-sec-butyl]-4-[p-[4-[p-[(2S\*, 4R\*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]- $\Delta^2$ -1,2,4-triazolin-5-one or ( $\pm$ )-1-[(RS)-sec-butyl]-4-[p-[4-[p-[(2R, 4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]- $\Delta^2$ -1,2,4-triazolin-5-one
- 15 (Itraconazole);
- 2-chloro-5-hydroxy-1,3-dimethylbenzene (Chloroxylenol);
- griseofulvin ultramicrosize (Griseofulvin);
- (E)-N-(6,6,-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride (Terbinafine);
- 25 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (Ciclopirox);
- N-4-tert-butyl-benzyl-N-methyl-1-naphthalenemethylamine hydrochloride (Butenafine
- 30 hydrochloride);

nystatin;

(E)-N-(Cinnamyl-N-methyl-1-naphthalenemethylamine  
hydrochloride (Naftifine hydrochloride);

2',4'-dichloro-2-imidazol-1-ylacetophenone (Z)-[O-  
5 (2,4-dichlorobenzyl)oxime] mononitrate (Oxiconazole  
nitrate),

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone  
(Ciclopirox);

selenium sulfide;

10 (±)-1-[4-(p-chlorophenyl)-2-[(2,6-  
dichlorophenyl)thio]butyl] imidazole mononitrate  
(Butoconazole nitrate);

([1-(o-chloro-.,.-diphenylbenzyl) imidazole])  
(Clotrimazole);

15 (cis-1-[p-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-  
triazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy phenyl]-  
4-isopropyl-piperazine (Tercanazole);

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone  
(ciclopirox);


20 and combinations thereof.

All patents, patent documents, and references  
cited herein are incorporated by reference.

Claims

What is claimed is:

1. A pharmaceutical composition comprising a triterpene and an essential oil.
2. The composition of claim 1 wherein the triterpene is a compound of formula (I):



wherein

- 15  $R_1$  is hydrogen or hydroxy;
- $R_2$  is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl,  $(C_6-C_{10})$ aryl, or  $(C_1-C_6)$ alkyl;
- $R_3$  is hydrogen, hydroxy, hydroxy $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkyl,  $O=P(OH)_2$ ,  $O=P(OH)_2OP(O)(OH)-$ ,  $(C_1-C_5)$ alkanoyl,  $Si(R)_3$  wherein each R is H, phenyl or  $(C_1-$
- 20

C<sub>6</sub>)alkyl, C(O)N(R)<sub>2</sub>, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C<sub>1</sub>-C<sub>4</sub>)alkoxy](C<sub>1</sub>-C<sub>4</sub>)alkyl, or a glycoside;

R<sub>4</sub> is hydrogen, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, O=P(OH)<sub>2</sub>, O=P(OH)<sub>2</sub>OP(O)(OH)-, (C<sub>1</sub>-C<sub>5</sub>)alkanoyl, Si(R)<sub>3</sub>, wherein each R is H, phenyl or (C<sub>1</sub>-C<sub>6</sub>)alkyl, C(O)N(R)<sub>2</sub>, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C<sub>1</sub>-C<sub>4</sub>)alkoxy](C<sub>1</sub>-C<sub>4</sub>)alkyl, or a glycoside; or R<sub>4</sub> and R<sub>5</sub> together are oxo; and

R<sub>5</sub> is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, or (C<sub>1</sub>-C<sub>6</sub>)alkyl; or R<sub>4</sub> and R<sub>5</sub> together are oxo;

wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C<sub>6</sub>-C<sub>10</sub>)aryl, nitro, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR<sub>7</sub>R<sub>8</sub>, wherein R<sub>7</sub> and R<sub>8</sub> are each independently hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or polyethyleneimine; or C(=O)OR<sub>9</sub>, wherein R<sub>9</sub> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or polyethyleneimine;

each of the bonds represented by --- is independently absent or is present;

wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol);

wherein any alkyl is optionally partially unsaturated;

wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR<sub>7</sub>R<sub>8</sub>, wherein R<sub>7</sub> and R<sub>8</sub> are each independently hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl or

polyethyleneimine; or  $C(=O)OR_9$ , wherein  $R_9$  is hydrogen,  
( $C_1-C_6$ )alkyl, or polyethyleneimine;  
or a pharmaceutically acceptable salt thereof.

5 3. The composition of claim 2 wherein the bond between  
carbons 1 and 2 is a single bond.

4. The composition of claim 2 wherein the bond between  
carbons 1 and 2 is a double bond.

10

5. The composition of any one of claims 2-4 wherein  $R_1$   
is hydrogen.

6. The composition of any one of claims 2-4 wherein  $R_1$   
15 is hydroxy.

7. The composition of any one of claims 2-6 wherein  $R_2$   
is a direct bond.

20 8. The composition of any one of claims 2-7 wherein  $R_3$   
is ( $C_1-C_6$ )alkyl; wherein

any alkyl can optionally be substituted with one or  
more oxo, carboxy, amino,  
-OP(=O)(OH)<sub>2</sub>, or phenyl;

25 any alkyl is optionally interrupted on carbon with  
one or more oxy or thio;

any alkyl is optionally partially unsaturated; and

any aryl can optionally be substituted with one or  
more hydroxy or carboxy.

30

9. The composition of any one of claims 2-8 wherein  $R_3$  is hydroxymethyl, (carboxymethoxy)acetoxymethyl, 4-carboxybutanoyloxymethyl, 3-carboxypropenoyloxymethyl, 2-carboxybenzoyloxymethyl, 3-carboxypropanoyloxymethyl, aminoacetoxymethyl, carboxycarbonyloxymethyl, 2-amino-3-methyl-butanoyloxymethyl, 4-carboxy-(3,3-dimethyl)butanoyloxymethyl, or  
 $-\text{CH}_2\text{OC}(=\text{O})\text{C}(=\text{O})-(\text{-NHCH}_2\text{CH}_2)_x-\text{[-N(CH}_2\text{CH}_2\text{NH}_2)\text{CH}_2\text{CH}_2]_y$ .
10. The composition of any one of claims 2-9 wherein  $R_4$  is hydrogen or  $(\text{C}_1\text{-C}_6)\text{alkyl}$ ; wherein  
 any alkyl can optionally be substituted with one or more oxo, carboxy, amino,  
 $-\text{OP}(=\text{O})(\text{OH})_2$ , or phenyl;  
 any alkyl is optionally interrupted on carbon with one or more oxy or thio;  
 any alkyl is optionally partially unsaturated; and  
 any aryl can optionally be substituted with one or more hydroxy or carboxy.
11. The composition of any one of claims 2-9 wherein  $R_4$  is hydrogen, hydroxymethyl, (carboxymethoxy)acetyl, 4-carboxybutanoyl, 3-carboxypropenoyl, 2-carboxybenzoyl, 3-carboxypropanoyl, aminoacetyl, carboxycarbonyl, 2-amino-3-methyl-butanoyl, 4-carboxy-(3,3-dimethyl)butanoyl, 3-carboxy-3-methylbutanoyl or  
 $\text{C}(=\text{O})\text{C}(=\text{O})-(\text{-NHCH}_2\text{CH}_2)_x-\text{[-N(CH}_2\text{CH}_2\text{NH}_2)\text{CH}_2\text{CH}_2]_y$ .
12. The composition of any one of claims 2-11 wherein  $R_5$  is oxy.



13. The composition of any one of claims 2-9 wherein R<sub>4</sub> and R<sub>5</sub> together are oxo.

5 14. The composition of claim 2 wherein

R<sub>1</sub> is hydrogen or hydroxy;

R<sub>2</sub> is a direct bond;

R<sub>3</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sub>4</sub> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and

10 R<sub>5</sub> is oxy or R<sub>4</sub> and R<sub>5</sub> together are oxo;

wherein

any alkyl can optionally be substituted with one or more oxo, carboxy, amino,

-OP(=O)(OH)<sub>2</sub>, or phenyl;

15 any alkyl is optionally interrupted on carbon with one or more oxy or thio;

any alkyl is optionally partially unsaturated; and

any aryl can optionally be substituted with one or more hydroxy or carboxy.

20

15. The composition of claim 2 wherein

R<sub>1</sub> is hydrogen or hydroxy;

R<sub>2</sub> is a direct bond;

R<sub>3</sub> is hydroxymethyl, (carboxymethoxy)acetoxymethyl,

25 4-carboxybutanoyloxymethyl, 3-carboxypropenoyloxymethyl,

2-carboxybenzoyloxymethyl, 3-carboxypropanoyloxymethyl,

aminoacetoxymethyl, carboxycarbonyloxymethyl, 2-amino-3-

methyl-butanoyloxymethyl, 4-carboxy-(3,3-

dimethyl)butanoyloxymethyl, or

30 -CH<sub>2</sub>OC(=O)C(=O)-(-NHCH<sub>2</sub>CH<sub>2</sub>)<sub>x</sub>-[-N(CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>)CH<sub>2</sub>CH<sub>2</sub>]<sub>y</sub>;


R<sub>4</sub> is hydrogen, hydroxymethyl,  
 (carboxymethoxy)acetyl, 4-carboxybutanoyl, 3-  
 carboxypropenoyl, 2-carboxybenzoyl, 3-carboxypropanoyl,  
 aminoacetyl, carboxycarbonyl, 2-amino-3-methyl-butanoyl,  
 5 4-carboxy-(3,3-dimethyl)butanoyl, 3-carboxy-3-  
 methylbutanoyl or -C(=O)C(=O)-(-NHCH<sub>2</sub>CH<sub>2</sub>)<sub>x</sub>-[-  
 N(CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>)CH<sub>2</sub>CH<sub>2</sub>]<sub>y</sub>.; and

R<sub>5</sub> is oxy or R<sub>4</sub> and R<sub>5</sub> together are oxo.

- 10 16. The composition of claim 2 wherein the triterpene  
 is betulin; betulin-3,28-diglycine; betulin-28-glycerol  
 oxalate; betulin-28-glycine; betulin-28-oxalate; betulin  
 arabinose galactan; betulin-3,28-diglycolate; betulin-3-  
 maleate; betulin-3,28-di-(L-glutamic acid  $\gamma$ -benzylester)  
 15 ester; betulin-3,28-di-L-alanine; betulin-3,28-di-L-  
 proline ester; betulin-3,28-dioxalate; betulin-1-ene-2-  
 ol; betulin-3,28-diphenylalanine; betulin-3,28-  
 dioxalate-polyethylene amine; betulin-3,28-diphosphate;  
 betulin-3-caffeate; betulin-3,28-(3',3'-  
 20 dimethyl)glutarate; betulin-28-diglycolate; betulin-28-  
 glutarate; betulin-28-maleate; betulin-28-phthalate;  
 betulin-3,28-di(3',3'-dimethyl) glutarate; betulin-3,28-  
 didiglycolate; betulin-3,28-dithiodiglycolate; betulin-  
 3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-  
 25 diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-  
 L-valine ester; betulin-28-succinate; betulin-3,28-  
 disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH  
 (Mw=1448); betulin-3,28-di-(polyethylene glycol)-COOH  
 (Mw=906); betulin-3,28-di-(polyethylene glycol)-COOH  
 30 (Mw=906); betulinic acid; betulon-1-ene-2-ol; betulin-

3,28-(dipoly(ethylene glycol)bis (carboxymethylester);  
 hederin hydrate; lupeol; lupeol-3-glutarate; lupeol-3-  
 succinate; lupeol-3-thiodiglycolate; lupeol-3-phthalate;  
 oleanolic acid; ursolic acid; uvaol; betulin oxalate;  
 5 betulin di-(L-glutamic acid  $\gamma$ -benzylester) ester;  
 betulin-3,28-di-L-proline; betulin-3,28-diphenylalanine  
 ester; betulin-3,28-phosphate; betulin-3,28-dioxalate-3-  
 polyethyleneimine; betulin-3,28-di(3',3'-  
 dimethyl)glutarate; betulin-3,28-dioxalate-3,28-  
 10 polyethyleneimine; betulin-3,28-di-L-valine; lupeol-3-  
 amine; lupeol-3-(3',3'-dimethyl)succinate; lupeol-3-  
 maleate; lupenone; or lupenon-1,2-ene-2-ol.

17. The composition of claim 1 wherein the triterpene  
 15 is a compound of formula (II):



(II)

20 wherein

one of  $R_1$  and  $R_2$  is -O-Y and the other is  
 hydrogen or  $(C_1-C_6)$ alkyl optionally substituted by  
 hydroxy,  $(C_1-C_6)$ alkoxy, halo, halo  $(C_1-C_6)$ alkoxy or  $NR_jR_k$

wherein  $R_j$  and  $R_k$  are independently H, (C<sub>1</sub>-C<sub>6</sub>)alkyl or (C<sub>1</sub>-C<sub>6</sub>)alkonyl; or  $R_1$  and  $R_2$  together are oxo (=O);

$R_3$  is hydrogen, halo, carboxy, mercapto, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, or -O-Y;

5  $R_4$  and  $R_5$  are each independently hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl;

$R_6$  is hydrogen or is absent when the adjacent -- is a bond;

$R_7$  is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

10  $R_8$  is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl and  $R_{11}$  is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, carboxy, or hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl; or  $R_8$  and  $R_{11}$  together are -O-C(=X)-;

$R_9$  and  $R_{10}$ , are each independently hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl;

15 each of the bonds represented by --- is independently absent or is present;

X is two hydrogens, oxo (=O) or thioxo (=S);

each Y is independently H, aryl, P(O)(Cl)<sub>2</sub>, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, adamantyl, -SO<sub>2</sub>R<sub>a</sub> O=P(R<sub>b</sub>)<sub>2</sub>,

20 O=P(R<sub>c</sub>)<sub>2</sub>OP(O)(R<sub>d</sub>)-, Si(R<sub>e</sub>)<sub>3</sub>, tetrahydropyran-2-yl, an amino acid, a peptide, a glycoside, or a 1 to 10 membered branched or unbranched carbon chain optionally comprising 1, 2, or 3 heteroatoms selected from non-peroxide oxy, thio, and -N(R<sub>f</sub>)-; wherein said chain may  
25 optionally be substituted on carbon with 1, 2, 3, or 4 oxo (=O), hydroxy, carboxy, halo, mercapto, nitro, -N(R<sub>g</sub>)(R<sub>h</sub>), (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>8</sub>)cycloalkyloxy, aryl, aryloxy, adamantyl, adamantyloxy, hydroxyamino, trifluoroacetylamino, a glycoside, an amino acid, or a  
30 peptide; and wherein said chain may optionally be

saturated or unsaturated (e.g. containing one, two, three or more, double or triple bonds);

$R_a$  is  $(C_1-C_6)$ alkyl or aryl;

$R_b$ ,  $R_c$ , and  $R_d$  are each independently hydroxy,   
 5  $(C_1-C_6)$ alkoxy, hydroxy $(C_2-C_6)$ alkoxy, adamantyloxy, adamantyl $(C_1-C_6)$ alkoxy, norbornyloxy, 1,1-di(hydroxymethyl)-2-hydroxyethoxy, carboxy $(C_1-C_6)$ alkoxy, 2,3-epoxypropyloxy, benzyloxy,  $(C_3-C_8)$ cycloalkyloxy,  $NR_xR_y$ , or aryloxy;

10  $R_e$  is H, aryl or  $(C_1-C_6)$ alkyl;

$R_f$  is hydrogen,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkanoyl, phenyl or benzyl;

$R_g$  and  $R_h$  are each independently selected from the group consisting of hydrogen,  $(C_1-C_6)$ alkyl,   
 15 hydroxy $(C_1-C_6)$ alkyl, adamantyl, adamantyl $(C_1-C_6)$ alkyl, amino $(C_1-C_6)$ alkyl, aminosulfonyl,  $(C_1-C_6)$ alkanoyl, aryl and benzyl; or  $R_b$  and  $R_c$  together with the nitrogen to which they are attached form a pyrrolidino, piperidino, or morpholino radical; and

20  $R_x$  and  $R_y$  are each independently hydrogen,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkanoyl, aryl or benzyl;

wherein each aryl of Y,  $R_a-R_d$ ,  $R_g-R_h$ ,  $R_x$ , and  $R_y$  may optionally be substituted by 1, 2, or 3 aminosulfonyl, carboxy,  $NR_iR_j$ ,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, hydroxy, halo, nitro, cyano, mercapto,   
 25 carboxy, hydroxy $(C_1-C_6)$ alkyl, halo $(C_1-C_6)$ alkyl, trifluoromethoxy,  $(C_1-C_6)$ alkanoyl,  $(C_1-C_6)$ alkoxycarbonyl,  $(C_1-C_6)$ alkylthio, or  $(C_1-C_6)$ alkanoyloxy; wherein  $R_i$  and  $R_j$  are each independently hydrogen,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkanoyl, phenyl, or benzyl;   
 30

wherein any alkyl can optionally be substituted with one or more polyethyleneimine or poly(ethylene glycol); and wherein any alkyl can optionally be interrupted with one or more  
5 polyethyleneimine or poly(ethylene glycol);  
or a pharmaceutically acceptable salt thereof.

18. The composition of claim 17 wherein the bond between carbons 1 and 2 is a single bond.

10

19. The composition of any one of claims 17-18 wherein  $R_1$  is -O-Y and Y is hydrogen, an amino acid, or ( $C_1$ - $C_6$ )alkyl; wherein

any alkyl can be optionally substituted with one or  
15 more oxo, hydroxy, amino, phenyl, or carboxy

any alky can be optionally interrupted with one or more oxy or thio;

any phenyl can be optionally substituted with one or more hydroxy or carboxy.

20

20. The composition of any one of claims 17-18 wherein  $R_1$  is -O-Y and Y is hydrogen, 3-carboxypropanoyl, 4-carboxybutanoyl, or 2-amino-2-methylbutanoyl.

21. The composition of any one of claims 17-20 wherein  $R_2$  is hydrogen.

22. The composition of any one of claims 17-21 wherein  $R_3$  is hydrogen.

30

23. The composition of any one of claims 17-22 wherein  
R<sub>4</sub> is methyl.

24. The composition of any one of claims 17-23 wherein  
5 R<sub>5</sub> is methyl.

25. The composition of any one of claims 17-24 wherein  
R<sub>6</sub> is hydrogen and the bond between carbons 12 and 13 is  
a single bond.

10

26. The composition of any one of claims 17-25 wherein  
R<sub>7</sub> is hydrogen.

27. The composition of any one of claims 17-26 wherein  
15 R<sub>8</sub> and R<sub>11</sub> together are -O-CH<sub>2</sub>-.

28. The composition of any one of claims 17-27 wherein  
R<sub>9</sub> is methyl.

20 29. The composition of any one of claims 17-28 wherein  
R<sub>10</sub> is methyl.

30. The composition of claim 17 wherein

R<sub>1</sub> is -O-Y and Y is hydrogen, an amino acid, or (C<sub>1</sub>-  
25 C<sub>6</sub>)alkyl; wherein

the alkyl of Y can be optionally substituted with  
one or more oxo, hydroxy, amino, carboxy, or phenyl  
optionally substituted with one or more hydroxy or  
carboxy;

and can be optionally interrupted with one or more  
oxy or thio;

R<sub>2</sub> is hydrogen;

R<sub>3</sub> is hydrogen and the bond between carbons 1 and 2  
5 is a single bond;

R<sub>4</sub> and R<sub>5</sub> are each methyl;

R<sub>6</sub> is hydrogen and the bond between carbons 12 and  
13 is a single bond;

R<sub>7</sub> is hydrogen

10 R<sub>8</sub> and R<sub>11</sub> together are -O-CH<sub>2</sub>-; and


R<sub>9</sub> and R<sub>10</sub> are each methyl.

31. The composition of claim 17 wherein the triterpene  
is 3- $\beta$ -acetoxy-19 $\alpha$ H-19,28 lactone oleanan; allobetulin;  
15 allobetulin-3-succinate; allobetulin-3-glycine;  
allobetulin lactone; allobetulin lactone-3-acetate;  
allobetulin lactone-3-phosphate; allobetulin-3-L-  
alanine; allobetulin-3-L-valine; allobetulin-3-L-  
proline; allobetulin-3-succinate; allobetulin-3-  
20 diglycolate; allobetulin-3-phthalate; allobetulin-3-  
methylenamine; allobetulin-3-ethanolamine; allobetulin-  
3-glycolate; allobetulin-3-glutarate; allobetulin-28-  
glutarate; allobetulin-3-methylamine HCl; allobetulin-3-  
phosphate; allobetulin-3-(polyethylene glycol)-COOH  
25 (Mw=674); allobetulon; allobetulon lactone 1-ene-2-ol;  
allobetulon lactone-1-en-2-succinate; allobetulon-1-ene-  
2-ol; allobetulon-1-ene-2-diglycolate; 3-allobetulon-1-  
ene-2-succinate; allobetulin-3-(poly(ethylene glycol))bis  
(carboxymethyl ester); or 3-allobetulon-1-ene-2-  
30 diglycolate.



32. The composition of claim 1 wherein the triterpene is a quaternary ammonium salt of a triterepene.

5 33. The composition of claim 1 wherein the triterpene is a compound of formula (III):



10

wherein

each  $R_1$  is independently absent, oxy, thio, or imino;

each  $R_2$  is independently absent or alkylene;

15 each  $R_3$  is independently hydrogen,  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, or  $-N^+R_aR_bR_c$ ; provided at least one  $R_3$  is  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, or  $-N^+R_aR_bR_c$ ;

20 wherein  $R_a$ ,  $R_b$ , and  $R_c$  are each independently ( $C_1$ - $C_{24}$ )alkyl, aryl, arylalkyl, heteroarylalkyl, heterocycle, or heterocylealkyl;

wherein each n is independently 0-4, provided at least one n is not 0;

wherein any heteroaryl, heterocycle, or  $R_a$ ,  $R_b$ , or  $R_c$  of  $R_3$  can optionally be substituted on carbon with one or more alkyl, hydroxyalkyl, arylalkyl, heteroarylalkyl, aryl, heterocycle, heterocyclealkyl, oxo, hydroxy, halo, nitro, cyano,  $(C_1-C_6)$ alkoxy, trifluoromethyl,  $-COOR_d$ ,  $-NR_dR_e$ , or cycloalkylalkyl;


wherein any cycloalkylalkyl can optionally be substituted on carbon with one or more hydroxyl,  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, or  $-N^+R_aR_bR_c$   $N^+$ -containing heteroarylalkyloxy,  $N^+$ -containing heterocyclealkyloxy, or  $-N^+R_aR_bR_cOxy$ ;

wherein  $R_d$  and  $R_e$  are each independently hydrogen or alkyl;

wherein any alkyl or alkylene of  $R_3$  can optionally be substituted on carbon with one or more oxo, hydroxy, halo, nitro, cyano,  $(C_1-C_6)$ alkoxy, trifluoromethyl,  $-COOR_d$ , or  $-NR_dR_e$ , and optionally interrupted on carbon with one or more oxy, imino, or thio, and is optionally partially unsaturated;

or an acceptable salt thereof.

34. The composition of claim 1 wherein the triterpene is a compound of formula (IV):



(IV)

wherein

5  $R_1$ ,  $R_4$ , and  $R_7$  are each independently absent or alkylene;

$R_3$  and  $R_6$  are each independently absent, oxy, thio, or imino;

10  $R_2$ ,  $R_5$ , and  $R_8$  are each independently hydrogen,  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, or  $-N^+R_aR_bR_c$ ; provided at least one of  $R_2$ ,  $R_5$ , and  $R_8$  is  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, or  $-N^+R_aR_bR_c$ ;

15 wherein  $R_a$ ,  $R_b$ , and  $R_c$  are each independently ( $C_1$ - $C_{24}$ )alkyl, aryl, arylalkyl, heteroarylalkyl, heterocycle, or heterocyclealkyl;

20 wherein any heteroaryl, heterocycle,  $R_a$ ,  $R_b$ , or  $R_c$  of  $R_2$ ,  $R_5$ , and  $R_8$  can optionally be substituted on carbon with one or more alkyl, hydroxyalkyl, arylalkyl, heteroarylalkyl, aryl, heterocycle, heterocyclealkyl, oxo, hydroxy, halo, nitro, cyano, ( $C_1$ - $C_6$ )alkoxy, trifluoromethyl,  $-COOR_d$ ,  $-NR_dR_e$ , or cycloalkylalkyl;

wherein any cycloalkylalkyl can optionally be substituted on carbon with one or more hydroxyl,  $N^+$ -

containing heteroaryl, N<sup>+</sup>-containing heterocycle, -  
N<sup>+</sup>R<sub>a</sub>R<sub>b</sub>R<sub>c</sub>, N<sup>+</sup>-containing heteroarylalkyloxy, N<sup>+</sup>-containing  
heterocyclealkyloxy, or -N<sup>+</sup>R<sub>a</sub>R<sub>b</sub>R<sub>c</sub>oxy;

wherein R<sub>d</sub> and R<sub>e</sub> are each independently hydrogen or  
5 alkyl;

wherein any alkyl or alkylene of R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>,  
or R<sub>8</sub> can be optionally substituted on carbon with one  
or more oxo, hydroxy, halo, nitro, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy,  
trifluoromethyl, -COOR<sub>d</sub>, or -NR<sub>d</sub>R<sub>e</sub>, and optionally  
10 interrupted on carbon with one or more oxy, imino, or  
thio, and is optionally partially unsaturated;  
or an acceptable salt thereof.

35. The composition of claim 34 wherein R<sub>2</sub>, R<sub>5</sub>, and R<sub>8</sub>  
15 are each independently absent, hydroxyl, N-  
diazabicyclo[2.2.2]octyl, N-pyridinium, N-alkyl-N-  
piperidino, N-alkyl-N-morpholino, N-  
azabicyclo[2.2.2]octyl, or -NR<sub>a</sub>R<sub>b</sub>R<sub>c</sub>; provided at least  
one of R<sub>2</sub>, R<sub>5</sub>, and R<sub>8</sub> is N<sup>+</sup>-containing heteroaryl, N<sup>+</sup>-  
20 containing heterocycle, or -N<sup>+</sup>R<sub>a</sub>R<sub>b</sub>R<sub>c</sub>;

wherein N-diazabicyclo[2.2.2]octyl; N-pyridinium;  
N-alkyl-N-piperidino; N-alkyl-N-morpholino; and N-  
azabicyclo[2.2.2]octyl can optionally be substituted on  
one or more suitable carbon atoms with one or more oxo,  
25 hydroxy, mercapto, alkyl, hydroxyalkyl, halo, nitro,  
cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -COOR<sub>d</sub>, or -NR<sub>d</sub>R<sub>e</sub>;

wherein any alkyl or alkylene of R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub>,  
or R<sub>8</sub> can optionally be substituted with one or more oxo  
or -NR<sub>d</sub>R<sub>e</sub>, and optionally interrupted with one or more

oxy, imino, or thio, and can optionally be partially unsaturated.

36. The composition of any one of claims 34-35 wherein  
5 R<sub>1</sub> is absent and R<sub>2</sub> is hydrogen, N-diazabicyclo[2.2.2]octyl, or N-dimethylamino-N-pyridinium.

37. The composition of any one of claims 34-36 wherein  
10 R<sub>3</sub> and R<sub>4</sub> are absent, and R<sub>5</sub> is hydrogen.

38. The composition of claim 34 wherein  
R<sub>3</sub> is oxy;  
R<sub>4</sub> is absent or (C<sub>1</sub>-C<sub>5</sub>)alkylenecarbonyl; and  
15 R<sub>5</sub> is hydrogen, N-diazabicyclo[2.2.2]octyl; 4-dimethylamino-N-pyridinium; 4-hydroxybutyl-N-diazabicyclo[2.2.2]octyl; 4-benzyl-N-diazabicyclo[2.2.2]octyl; tetramethylethylenediamine-N-yl; N'-benzyl-N,N,N',N'-tetramethylethylenediamine-N-yl;  
20 N-pyridinium; 4-hydroxymethyl-N-pyridinium; 2,4-dimethyl-N-pyridinium; 3,5-dimethyl-N-pyridinium; octyldimethylammonium; or tetradecyldimethylammonium.

39. The composition of claim 34 wherein  
25 R<sub>6</sub> is oxy;  
R<sub>7</sub> is absent or (C<sub>1</sub>-C<sub>5</sub>)alkylenecarbonyl; and  
R<sub>8</sub> is hydrogen, N-diazabicyclo[2.2.2]octyl; 4-dimethylamino-N-pyridinium; N'-(4-hydroxybutyl)-N-diazabicyclo[2.2.2]octyl; N'-benzyl-N-  
30 diazabicyclo[2.2.2]octyl; N,N,N',N'-

tetramethylethylenediamine-N-yl; N'-benzyl-N,N,N',N'-  
 tetramethylethylenediamine-N-yl; N-pyridinium; 4-  
 hydroxymethyl-N-pyridinium; 2,4-dimethyl-N-pyridinium;  
 3,5-dimethyl-N-pyridinium; octyldimethylammonium;  
 5 tetradecyldimethylammonium; 2-methyl-N-pyridinium; 4-  
 hydroxy-N-methyl-N-piperidinium; or N-methyl-N-  
 morpholino.

40. The composition of claim 1 wherein the triterpene  
 10 is  
 lup-20(29)-ene-3,28-bis-(N-pyridiniumacetate);  
 lup-20(29)-ene-3-[N-(4-oxybutyl)-1,4-  
 diazabicyclo[2.2.2]octyl-N'-acetate];  
 lup-20(29)-ene-3,28-bis[N-(1,4-  
 15 diazabicyclo[2.2.2]octyl)acetate];  
 lup-20(29)-ene-3,28-bis[N-(N'-  
 benzyl)diazabicyclo[2.2.2]octyl)acetate];  
 lup-20(29)-ene-3,28-bis[N-(N'-(4-  
 oxybutyl)diazabicyclo[2.2.2]octyl)acetate];  
 20 lup-20(29)-ene-3-[N-(1,4-  
 diazabicyclo[2.2.2]octyl)acetate];  
 lup-20(29)-ene-3,28-bis[(tetramethylethylenediamine-N-  
 yl)acetate];  
 lup-20(29)-ene-3,28-bis[(N'-benzyl-N,N,N',N'-  
 25 tetramethylethylenediamine-N-yl)acetate];  
 lup-20(29)-ene-3-[N-(N'-  
 (benzyl)diazabicyclo[2.2.2]octyl)acetate];  
 bis(N,N'-pyridinium-2-ethyl)lup-20(29)-ene-3,28-  
 dicarbamate;


- 1- (3,28- (diacetoxy) lup-20 (29) -ene-30-yl) -4-  
(dimethylamino)pyridinium;  
lup-20 (29) -ene-3,28-bis (N-pyridinium-2-propionate) ;  
lup-20 (29) -ene-3,28-bis (N-pyridinium-3-propionate) ;  
5 lup-20 (29) -ene-3,28-bis (N-pyridinium-4-butyrate) ;  
lup-20 (29) -ene-3,28-bis (N-pyridinium-4-butyrate) ;  
lup-20 (29) -ene-3,28-bis (N-pyridinium-2-butyrate) ;  
1- [3,28- (diacetoxy) lup-20 (29) -ene-30-yl] -1,4-  
diazabicyclo[2.2.2]octyl ;  
10 3,28-bis[3- (1-piperidiny)propanoyloxy] lup-20 (29) -ene ;  
1- (3,28-dihydroxylup-20 (29) ene-30-yl) -4-  
(dimethylamino)pyridinium;  
lup-20 (29) -ene-3,28-bis[N- (4-dimethylaminopyridinium) -2-  
propionate] ;  
15 lup-20 (29) -ene-3,28-bis[N- (1,4-  
diazabicyclo[2.2.2]octyl) -2-propionate] ;  
1- (lup-20 (29) -ene-30-yl) -1,4-diazabicyclo[2.2.2]octane ;  
1- (3,28-dihydroxylup-20 (29) -ene-30-yl) -pyridinium;  
lup-20 (29) -ene-3,28-bis[N- (1,4-  
20 diazabicyclo[2.2.2]octyl) -4-butyrate] ;  
1- (3,28-dihydroxylup-20 (29) -ene-30-yl) - [N-3-  
(hydroxymethyl)pyridinium] ;  
1- (3,28-dihydroxylup-20 (29) -ene-30-yl) - [N- (3,5-  
dimethylpyridinium) ] ;  
25 bis[N- (1,4-diazabicyclo[2.2.2]octyl) -2-ethyl] -lup-  
20 (29) ene-3,28-dicarbamate ;  
lup-20 (29) -ene-3,28-bis[N- (3-  
oxymethylpyridinium) acetate] ;  
lup-20 (29) -ene-3,28-bis[N- (2-  
30 oxymethylpyridinium) acetate] ;

- lup-20 (29) -ene-3,28-bis [N- (2-methylureapyridinium) acetate] ;
- lup-20 (29) -ene-3- [N- (2-oxymethylpyridinium) acetate] ;
- lup-20 (29) -ene-3,28-bis [N- (N-methylmorpholino) acetate] ;
- 5 lup-20 (29) -ene-3,28-bis [N- (4-hydroxyl-N-methylpiperidino) acetate] ;
- lup-20 (29) -ene-3- [N- (3-ureamethylpyridinium) acetate] ;
- lup-20 (29) -ene-3- (N-pyridiniumacetate) ;
- lup-20 (29) -ene-3,28-bis [N- (1,4-
- 10 diazabicyclo[2.2.2]octyl) -2-butyrate] ;
- lup-20 (29) -ene-3,28-bis [N- (4-dimethylpyridinium) -2-butyrate] ;
- lup-20 (29) -ene-3,28-bis [N- (4-dimethylaminopyridinium) -4-butyrate] ;
- 15 lup-20 (29) -ene-3,28-bis [N- (4-dimethylaminopyridinium) -3-propionate] ;
- 1- (3,28-dihydroxylup-20 (29) -ene-30-yl) -4- (hydroxymethyl) pyridinium;
- 1- (3,28-dihydroxylup-20 (29) -ene-30-yl) -3-hydroxy-1-
- 20 azabicyclo[2.2.2]octane;
- lup-20 (29) -ene-3,28-bis [N- (2,4-dimethylpyridinium) acetate] ;
- lup-20 (29) -ene-3,28-bis [N- (3,5-dimethylpyridinium) acetate] ;
- 25 lup-20 (29) -ene-3,28-bis [N- (4-dimethylaminopyridinium) acetate] ;
- lup-20 (29) -ene-3- [N- (2-methylpyridinium) acetate] ;
- lup-20 (29) ene-3- [N- (2,4-dimethylpyridinium) acetate] ;
- lup-20 (29) -ene-3- [N- (4-hydroxy-N-
- 30 methylpiperidino) acetate] ;



- lup-20(29)-ene-3-[N-(N-methylmorpholino)acetate];  
 lup-20(29)-ene-3-[N-(3,5-dimethylpyridinium)acetate];  
 lup-20(29)-ene-3-[N-(4-dimethylaminopyridinium)acetate];  
 lup-20(29)-ene-3,28-bis(octyldimethylammoniumacetate);  
 5 lup-20(29)-ene-3-octyldimethylammoniumacetate;  
 lup-20(29)-ene-3,28-  
 bis(tetradecyldimethylammoniumacetate);  
 lup-20(29)-ene-3-tetradecyldimethylammoniumacetate;  
 N,N,N',N'-tetramethylethylenediamine-N,N'-bis-[lup-  
 10 20(29)-ene-3-acetate];  
 1-[(lup-20(29)-en-3-yl)oxycarbonylmethyl]-4-aza-1-  
 azonia-bicyclo[2.2.2]octane;  
 1-[(lup-20(29)-en-3-yl)oxycarbonylmethyl]trimethylammonium; or  
 15 1-[(lup-20(29)-en-3-yl)oxycarbonylmethyl]pyridinium.

41. The composition of claim 1 wherein the triterpene is a compound of formula (V):



(v)


wherein

- each  $R_1$  is independently absent, oxy, thio, or imino;
- each  $R_2$  is independently absent or alkylene;
- each  $R_3$  is independently hydrogen,  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, or  $-N^+R_aR_bR_c$ ;
- 5 provided at least one  $R_3$  is  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, or  $-N^+R_aR_bR_c$ ;
- $R_4$  is hydrogen, alkyl, or hydroxyalkyl;
- or  $R_4$  together with one  $R_1R_2R_3$  forms a  $-OCH_2-$
- 10 bridging carbons 19 and 17;
- wherein  $R_a$ ,  $R_b$ , and  $R_c$  are each independently ( $C_1$ - $C_{24}$ )alkyl, aryl, arylalkyl, heteroarylalkyl, heterocycle, or heterocyclealkyl;
- wherein each  $n$  is independently 0-4, provided at
- 15 least one  $n$  is not 0;
- wherein any heteroaryl, heterocycle, or  $R_a$ ,  $R_b$ , or  $R_c$  of  $R_3$  can optionally be substituted on carbon with one or more alkyl, hydroxyalkyl, arylalkyl, heteroarylalkyl, aryl, heterocycle, heterocyclealkyl, oxo, hydroxy, halo,
- 20 nitro, cyano, ( $C_1$ - $C_6$ )alkoxy, trifluoromethyl,  $-COOR_d$ ,  $-NR_dR_e$ , or cycloalkylalkyl;
- wherein any cycloalkylalkyl can optionally be substituted on carbon with one or more hydroxyl,  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle,  $-N^+R_aR_bR_c$ ,
- 25  $N^+R_aR_bR_c$ ,
- $N^+$ -containing heteroarylalkyloxy,  $N^+$ -containing heterocyclealkyloxy, or  $-N^+R_aR_bR_c$ oxy;
- wherein  $R_d$  and  $R_e$  are each independently hydrogen or alkyl;

wherein any alkyl or alkylene of  $R_3$  can optionally be substituted on carbon with one or more oxo, hydroxy, halo, nitro, cyano,  $(C_1-C_6)$ alkoxy, trifluoromethyl,  $-COOR_d$ , or  $-NR_dR_e$ , and optionally interrupted on carbon  
 5 with one or more oxy, imino, or thio, and is optionally partially unsaturated

or an acceptable salt thereof.

42. The composition of claim 1 wherein the triterpene  
 10 is a compound of formula (VI)



(VI)

wherein

- 15  $R_1$  is hydrogen, alkyl, or hydroxyalkyl,  
 $R_2$  is oxymethylene, thiomethylene, iminomethylene, or methylene;  
 $R_3$  and  $R_6$  are each independently absent or alkylene;  
 $R_4$  and  $R_7$  are each independently hydrogen,  $N^+$ -  
 20 containing heteroaryl,  $N^+$ -containing heterocycle, or  $-NR_aR_bR_c$ ; provided at least one of  $R_4$  and  $R_7$  is  $N^+$ -containing heteroaryl,  $N^+$ -containing heterocycle, -

$\text{NR}_a\text{R}_b\text{R}_c$ ; or  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ , and  $\text{R}_4$  are together  $-\text{O}-\text{C}(=\text{X})-$ ;

wherein  $\text{X}$  is two hydrogens, oxo, or thioxo ( $=\text{S}$ );

wherein  $\text{R}_a$ ,  $\text{R}_b$ , and  $\text{R}_c$  are each independently ( $\text{C}_1$ - $\text{C}_{24}$ )alkyl, aryl, arylalkyl, heteroarylalkyl, heterocycle,  
5 or heterocyclealkyl;

wherein  $\text{R}_5$  is absent, oxy, thio, or imino;

wherein any heteroaryl, heterocycle, or  $\text{R}_a$ ,  $\text{R}_b$ , or  
 $\text{R}_c$  of  $\text{R}_4$  and  $\text{R}_7$  can optionally be substituted on carbon  
with one or more alkyl, hydroxyalkyl, arylalkyl,  
10 heteroarylalkyl, aryl, heterocycle, heterocyclealkyl,  
oxo, hydroxy, halo, nitro, cyano, ( $\text{C}_1$ - $\text{C}_6$ )alkoxy,  
trifluoromethyl,  $-\text{COOR}_d$ ,  $-\text{NR}_d\text{R}_e$ , or cycloalkylalkyl;

wherein any cycloalkylalkyl can optionally be  
substituted on carbon with one or more hydroxyl,  $\text{N}^+$ -  
15 containing heteroaryl,  $\text{N}^+$ -containing heterocycle, -  
 $\text{N}^+\text{R}_a\text{R}_b\text{R}_c$ ,  $\text{N}^+$ -containing heteroarylalkyloxy,  $\text{N}^+$ -containing  
heterocyclealkyloxy, or  $-\text{N}^+\text{R}_a\text{R}_b\text{R}_c\text{oxy}$ ;

wherein  $\text{R}_d$  and  $\text{R}_e$  are each independently hydrogen or  
alkyl;

20 wherein any alkyl or alkylene of  $\text{R}_3$ ,  $\text{R}_4$ ,  $\text{R}_6$ , or  $\text{R}_7$   
can be optionally substituted on carbon with one or more  
oxo, hydroxy, halo, aryl, nitro, cyano, ( $\text{C}_1$ - $\text{C}_6$ )alkoxy,  
trifluoromethyl,  $\text{COOR}_d$ , or  $-\text{NR}_d\text{R}_e$ , and optionally  
interrupted on carbon with one or more oxy, imino, or  
25 thio, and is optionally partially unsaturated;

or an acceptable salt thereof.

43. The composition of claim 42 wherein

$\text{R}_1$  is hydrogen, alkyl, or hydroxyalkyl,

R<sub>2</sub> is oxymethylene, thiomethylene, iminomethylene, or methylene;

R<sub>3</sub> and R<sub>6</sub> are each independently absent or (C<sub>1</sub>-C<sub>5</sub>)alkylenecarbonyl;

5 R<sub>4</sub> and R<sub>7</sub> are each independently hydrogen, N-diazabicyclo[2.2.2]octyl; N-pyridinium; N-alkyl-N-piperidino; N-alkyl-N-morpholino; N-azabicyclo[2.2.2]octyl; or NR<sub>a</sub>R<sub>b</sub>R<sub>c</sub>;

or R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are together -O-CH<sub>2</sub>-;

10 wherein N-diazabicyclo[2.2.2]octyl; N-pyridinium; N-alkyl-N-piperidino; N-alkyl-N-morpholino; and N-azabicyclo[2.2.2]octyl can optionally be substituted on carbon with one or more alkyl, hydroxyalkyl, hydroxy, COOR<sub>d</sub>, or NR<sub>d</sub>R<sub>e</sub>;

15 wherein R<sub>a</sub>, R<sub>b</sub>, and R<sub>c</sub> are each independently aryl or (C<sub>1</sub>-C<sub>24</sub>)alkyl; wherein R<sub>d</sub> and R<sub>e</sub> are each independently hydrogen or alkyl;

wherein any alkylene or alkyl can optionally be substituted on carbon with one or more oxo, hydroxy, 20 halo, nitro, cyano, trifluoromethyl, COOR<sub>d</sub>, or -NR<sub>d</sub>R<sub>e</sub>, and optionally interrupted with one or more oxy, imino, or thio, and where any alkyl or alkylene can optionally be partially unsaturated.

25 44. The composition of any one of claims 42-43 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are together -O-CH<sub>2</sub>-.

45. The composition of any one of claims 42-44 wherein R<sub>5</sub> is oxy.

30

46. The composition of any one of claims 42-45 wherein  $R_6$  is acetyl.

47. The composition of any one of claims 42-46 wherein  
5  $R_7$  is N-diazabicyclo[2.2.2]octyl; N-pyridinium; or -  
 $N^+(CH_3)_3$ .

48. The composition of claim 42 wherein the cation of  
the compound is  
10 1-[(19,28-epoxy-18-oleanan-3-yl)oxycarbonylmethyl]-4-  
aza-1-azonia-bicyclo[2.2.2]octane;  
[(19,28-epoxy-18-oleanan-3-  
yl)oxycarbonylmethyl]trimethylammonium; or  
1-[(19,28-epoxy-18-oleanan-3-  
15 yl)oxycarbonylmethyl]pyridinium.

49. The composition of any one of claims 1-48 wherein  
the triterpene is present up to about 30 wt.% of the  
composition.

20

50. The composition of any one of claims 1-49 wherein  
the triterpene is present up to about 20 wt.% of the  
composition.

25 51. The composition of any one of claims 1-50 wherein  
the triterpene is present up to about 10 wt.% of the  
composition.

52. The composition of any one of claims 1-51 wherein the triterpene is present up to about 5 wt.% of the composition.
- 5 53. The composition of any one of claims 1-52 wherein the essential oil is at least one of ajowan, almond oil, sweet almond oil, allspice, aloe vera oil, ammi visnaga (khella), amyris, angelica root, angelica seed, anise, anise seed, star anise, apricot kernel oil, absolute
- 10 arnica, avocado oil, unrefined avocado oil, Copaiba balsam, balsam Peru genuine, balsam Peru oil, balsam peru liquid resin, balsam tolu, sweet french basil, basil, basil ct. methyl chavicol, lemon ct. citral basil, sweet ct. linalool basil, bay laurel, bay leaf,
- 15 bay rum, bay leaf West Indies, bees wax, unrefined bees wax, benzoin absolute, benzoin resinoid, bergamot, mint bergamot, Italian bergamot oil, free bergaptene bergamot, birch, sweet birch, borage oil, boronia, butter, buchu leaf, cajeput, calamus, calendula oil,
- 20 infused calendula oil, camellia oil, camphor, cannabis, caraway, caraway seed, cardamom, absolute carnation, carrot seed, high carotol carrot seed, carrot seed oil, cassia, cassis bud (black currant), castor oil, catnip, oil of catnip, cedarleaf, western red cedarleaf,
- 25 cedarwood, Atlas cedarwood, Himalayan cedarwood, Virginia cedarwood, celery seed, chamomile, blue chamomile, German chamomile, Moroccan chamomile, Moroccan wild chamomile, Roman chamomile, champaca, cilantro, true cinnamon bark, cinnamon bark, cinnamon
- 30 leaf, cinnamon cassia, cistus, citronella, Java

- citronella, ciste oil, artificial civet, clary sage,  
high sclareol clary sage, clementine, Italian clementine  
peel oil, clove, clove bud, clove leaf, cocoa, cocoa  
butter, unrefined cocoa butter, coconut oil, refined  
5 coconut oil, cognac, coltsfoot, combava petitgrain,  
coriander, green coriander, cornmint, costus oil, cumin,  
cypress, davana oil, dill, dill weed, elemi, ephedra,  
erigeron (fleabane), eucalyptus, eucalyptus citriodora,  
eucalyptus globulus, lemon eucalyptus, fennel, sweet  
10 fennel, fenugreek, fir, fir needle oil, Canada fir  
needle, Siberia fir needle, white fir needle,  
frankincense, India frankincense, Oman frankincense,  
galbanum oil, garlic, genet, geranium, geranium leaf,  
geranium rose, Bourbon geranium, Egyptian geranium,  
15 ginger, Cochin extra ginger, ginseng, Siberian ginseng,  
Korean ginseng, grapefruit, pink grapefruit, white  
grapefruit, grapeseed oil, hazelnut oil, helichrysum,  
helichrysum immortelle, Mad. helichrysum, Balkan  
helichrysum, Corsica helichrysum, France helichrysum,  
20 hemp oil, absolute honeysuckle, hyssop, hyssop  
decumbens, absolute immortelle, fragrant aster inula,  
Jamaican gold, unrefined Jamaican gold, jasmine,  
absolute jasmine, grandiflorum jasmine, sambac jasmine,  
jojoba oil, helio-carrot in jojoba, melissa in jojoba,  
25 absolute jonquille, juniper berry, Siberia juniper  
berry, Croatia juniper berry, lanolin, unrefined  
anhydrous lanolin, lantana camara, laurel nobilis,  
lavandin, abrialis lavandin, grosso lavandin, lavender,  
Oregon lavender, Bulgarian lavender, Russian lavender,  
30 high-altitude lavendar, wild-crafted lavender, lavandin,



organic lavandin, lemon, lemongrass, lime, distilled  
lime, expressed lime, litsea, litsea cubeba, blue, pink  
and white lotus, macadamia oil, mace, green mandarin,  
red mandarin, yellow mandarin, manuka, absolute  
5 marigold, marigold flower, marjoram, Spanish marjoram,  
sweet marjoram (true), massoia bark, melissa,  
codistilled melissa, "rectified" melissa, true melissa,  
menthol, methyl salicylate, absolute mimosa, mimosa,  
monarda, mugwort, musk seed, myrrh, myrtle, absolute  
10 narcissus, neroli (orange blossom), niaouli, nutmeg,  
extra nutmeg, oakmoss, absolute oak moss, olibanum,  
absolute opopanax, orange, bitter orange, blood orange,  
sweet orange, wild West Indian orange, oregano, orris  
root, concrete orris, osmanthus, palm oil, refined palm  
15 oil, palmarosa, paprika, parsley seed, patchouli, Indian  
patchouli oil, Indonesian patchouli oil, peanut, peanut  
oil, pecan oil, pennyroyal, pepper, black pepper, super  
black pepper, peppermint, India peppermint, USA baby  
mint peppermint, pet perfume, petitgrain (orange  
20 leaves), white pine, pine needle, evening primrose,  
ravensara anisata, true ravensara, ravensara,  
ravintsara, redberry, rosalina, rose, rose geranium,  
rose otto, Bulgarian rose, English rose, Turkish rose,  
rosehip seed oil, rosemary, rosemary anti-oxidant  
25 extract powder, rosemary verbenone, Morocco rosemary,  
Spain rosemary, rosewood, rosewood oil, rue, sage, white  
sage, sage dalmatian, sage officinalis, sage triloba,  
sandalwood, sassafras, seabuckthorn berry, sesame oil,  
sesame seed oil, shea butter, unrefined shea butter,  
30 spearmint, spikenard, green spikenard, spruce, St.

- John's wort, styrax resin, tagetes, tangerine, Dancy  
tangerine, tarragon, tea tree, Australia tea tree, thuja  
(cedar leaf), thyme, red thyme, thyme ct. linalool,  
thyme vulgaris, wild thyme, red thyme, thymol, mixed  
5 tocopherols, tolu balsam resin, absolute tuberose,  
tuberose, tumeric, valerian, vanilla, pure vanilla  
extract, vanilla bean, absolute vanilla bourbon,  
vegetable glycerin, absolute verbena, vetiver, violete  
leaves, vitex, organic Haiti vetiver, absolute violet  
10 leaf, walnut oil, wintergreen, natural wintergreen,  
wormwood, yarrow, ylang ylang, ylang ylang I, ylang  
ylang II, ylang ylang III, ylang ylang compound, ylang  
ylang complete, and ylang ylang extra.
- 15 54. The composition of any one of claims 1-53 wherein  
the essential oil comprises at least one of menthol,  
camphor, eucalyptus oil, cedarleaf oil, nutmeg oil,  
thymol, and turpentine oil.
- 20 55. The composition of any one of claims 1-54 wherein  
the essential oil is present in a total amount of up to  
about 90 wt.% of the composition.
- 25 56. The composition of any one of claims 1-55 wherein  
the essential oil is present in a total amount of up to  
about 80 wt.% of the composition.
- 30 57. The composition of any one of claims 1-56 wherein  
the essential oil is present in a total amount of up to  
about 70 wt.% of the composition.

58. The composition of any one of claims 1-57 wherein the essential oil is present in a total amount of up to about 60 wt.% of the composition.

5

59. The composition of any one of claims 1-58 further comprising water.

60. The composition of any one of claims 1-59 further comprising at least one of petrolatum, mineral oil, ceresin, and lanolin alcohol.

10

61. The composition of any one of claims 1-60 further comprising an absorption enhancer.

15

62. The composition of claim 61 wherein the absorption enhancer comprises at least one of water, methanol, ethanol, 2-propanol, dimethyl sulfoxide, decylmethyl sulfoxide, tetradecyl methyl sulfoxide, 2-pyrrolidone, N-methyl-2-pyrrolidone, N-(2-hydroxyethyl) pyrrolidone, laurocapram, acetone, dimethyl acetamide, dimethyl formamide, tetrahydrofurfuryl alcohol, docusate sodium, sodium lauryl sulfate, quaternary ammonium salt, lecithin, cephalin, alkylbetamine, monoglyceride, diglycexide, triglyceride, lauryl alcohol, cetyl alcohol, stearyl alcohol, sucrose, sorbitan, polyethylene glycol, urea, and N,N-diethyl-m-toluamide.

20

25

63. The composition of any one of claims 1-62 further comprising a polyhydric alcohol selected from the group

30

of glycerin, ethylene glycol, polyethylene glycol, propylene glycol, triethylene glycol, tetraethylene glycol, sorbitol, and combinations thereof.

- 5 64. The composition of any one of claims 1-63 further comprising a skin protectant selected from the group of  
 10 aloe, glycerin, calamine, Vitamin E, Vitamin E acetate, Vitamin C, allantoin, aluminum hydroxide gel, bismuth subnitrate, boric acid, calamine, cocoa butter, dimethicone, glycerin, kaolin, live yeast cell  
 15 derivative, petrolatum, pyridoxine hydrochloride, shark liver oil, sodium bicarbonate, sulfur, tannic acid, topical starch, mineral oil, ceresin, bisabolol, panthenol, trolamine, white petrolatum, zinc acetate, zinc carbonate zinc oxide, zinc sulfate, and combinations thereof.

65. The composition of any one of claims 1-64 further comprising an anti-infective agent selected from the  
 20 group of:

[1R-(1R\*, 3S\*, 5R\*, 6R\*, 9R\*, 11R\*, 15S\*, 16R\*, 17R\*, 18S\*, 19E, 21E, 23E, 25E, 27E, 29E, 31E, 33R\*, 35S\*, 36R\*, 37S\*)]-33-[(3-Amino-3,6-dideoxy- $\beta$ -D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-  
 25 15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid (Amphotericin B);  
 5-fluorocytosine (Flucytosine);  
 2,4-difluoro- $\alpha$ , $\alpha$ <sup>1</sup>-bis(1H-1,2,4-triazol-1-ylmethyl)  
 30 benzyl alcohol) (Fluconazole);

griseofulvin microsize (Griseofulvin);

(E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride (Terbinafine);

5 cis-1-acetyl-4-[4-[(2-(2,4-dichlorophenyl)-2-(1H-imadazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxyl]phenyl] piperazine (Ketoconazole);

(±)-1-[(R\*)-sec-butyl]-4-[p-[4-[p-[(2R\*,4S\*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<sup>2</sup>-1,2,4-triazolin-5-one mixture  
 10 with (±)-1-[(R\*)-sec-butyl]-4-[p-[4-[p-[(2S\*,4R\*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<sup>2</sup>-1,2,4-triazolin-5-one or (±)-1-[(RS)-sec-butyl]-4-[p-[4-[p-[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]-Δ<sup>2</sup>-1,2,4-triazolin-5-one  
 15 (Itraconazole);

2-chloro-5-hydroxy-1,3-dimethylbenzene  
 20 (Chloroxylonol);

griseofulvin ultramicrosize (Griseofulvin);

(E)-N-(6,6,-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride (Terbinafine);

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone  
 25 (Ciclopirox);

N-4-tert-butyl-benzyl-N-methyl-1-naphthalenemethylamine hydrochloride (Butenafine hydrochloride);

nystatin;

(E)-N-(Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride (Naftifine hydrochloride);

2',4'-dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime] mononitrate (Oxiconazole  
5 nitrate),

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone (Ciclopirox);

selenium sulfide;

(±)-1-[4-(p-chlorophenyl)-2-[(2,6-  
10 dichlorophenyl)thio]butyl] imidazole mononitrate (Butoconazole nitrate);

[[1-(o-chloro-...-diphenylbenzyl) imidazole]] (Clotrimazole);

(cis-1-[p-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-  
15 triazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy phenyl]-4-isopropyl-piperazine (Tercanazole);

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone (ciclopirox);

and combinations thereof.

20

66. An anti-fungicidal composition comprising a composition of any one of claims 1-65 and a fungicidal excipient.

25

67. The composition of any one of claims 1-66 which is a cream.

68. The composition of any one of claims 1-66 which is a gel.

30

69. The composition of any one of claims 1-66 which is an ointment.

70. The composition of any one of claims 1-66 which is  
5 a lotion.

71. The composition of any one of claims 1-70 for use in medical therapy.

10 72. The use of a composition of any one of claims 1-70, for the manufacture of a medicament for treating a mammal afflicted with a fungal infection.

73. The use of a composition of claim 72, wherein the  
15 mammal is a human.

74. The use of a composition of any one of claims 72-73, wherein the fungal infection is caused by a dermatophytic fungus.

20

75. The method of claim 74 wherein the dermatophytic fungus is *Microsporum canis*, *Microsporum gypseum*, *Microsporum audouinii*, *Trichophyton tonsurans*, *Trichophyton mentagrophytes*, *Epidermophyton floccosum*,  
25 *Trichophyton rubrum*, or *Pityrosporum ovale*.

76. The use of a composition of any one of claims 72-73, wherein the fungal infection is caused by *Candida albicans* or *Candida guilliermoundi*.

30

77. The use of a composition of any one of claims 72-73, wherein the fungal infection is caused by *Blastomyces dermatidis* or *Cryptococcus neoformans*.
- 5 78. The use of a composition of any one of claims 72-77, wherein the fungal infection is present on a nail of the mammal, under the nail of the mammal, or a combination thereof.
- 10 79. The use of a composition of any one of claims 72-77, wherein the fungal infection is present on a toe-nail of the mammal, under the toe-nail of the mammal, or a combination thereof.
- 15 80. The use of a composition of any one of claims 72-77, wherein the fungal infection is present on the scalp of the mammal.
- 20 81. The use of a composition of any one of claims 72-77, wherein the fungal infection is present on the vagina of the mammal, in the vagina of the mammal, or a combination thereof.
- 25 82. The use of a composition of any one of claims 72-77, wherein the fungal infection is present on a skin surface of the mammal.
83. A method of inhibiting or killing a fungus comprising contacting the fungus with an effective anti-



5 fungal amount of a composition of any one of claims 1-70.

84. The method of claim 83 wherein the contacting is *in vitro*.

85. The method of claim 83 wherein the contacting is *in vivo*.

10 86. The method of claim 83 wherein the fungal infection is present on plant tissue.

87. The method of claim 83 wherein the fungus is present on turf grass.

15

88. The method of claim 83 wherein the fungus causes the disease dollar spot or brown patch.

89. The method of claim 86 wherein the plant tissue  
20 comprises bark, roots, leaves, flowers, needles, bulbs, berries, rhizomes, rootstocks, stems, seeds, or any combination thereof.

**THIS PAGE BLANK (USPTO)**

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/089357 A3**

(51) International Patent Classification<sup>7</sup>: **C07J 63/00**,  
A61K 31/56, A61P 31/10

(21) International Application Number:  
PCT/US2004/010351

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/459,742 2 April 2003 (02.04.2003) US

(71) Applicant (for all designated States except US): **RE-  
GENTS OF THE UNIVERSITY OF MINNESOTA**  
[US/US]; 450 McNamara Alumni Center, 200 Oak Street  
S.E., Minneapolis, MN 55455-2070 (US).

(71) Applicants and

(72) Inventors: **CARLSON, Robert, M.** [US/US]; 2231 East  
Third Street, Duluth, MN 55812 (US). **GIBSON, David, J.**  
[US/US]; 1339 Vallee Drive, Woodbury, NJ 08096 (US).

(74) Agents: **CLISE, Timothy, B.** et al.; Schwegman, Lund-  
berg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN  
55402 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
29 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL

(57) Abstract: The present invention provides for pharmaceutical compositions that includes a triterpene (e.g., betulin) and an es-  
sential oil (Vicks® Vapor Rub). The present invention also provides for a cosmetic formulation that includes a triterpene (e.g.,  
betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides a method of treating a fungal infection  
that includes administering (e.g., topically applying) an effective amount of the pharmaceutical composition to the tissue afflicted  
with the fungal infection, or the tissue at risk of being afflicted with the fungal infection.



WO 2004/089357 A3

**THIS PAGE BLANK (USPTO)**

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07J63/00 A61K31/56 A61P31/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/092712 A (MITAKOU SOFIA ; FOTINOS SPIROS (GR); ZERVOLEA IRENE (GR); KLETSAS DIMI) 13 November 2003 (2003-11-13) tables 15,17,19	1,16,59, 66,67,71
X	ALI-SHTAYEH M S ET AL: "ANTIFUNGAL ACTIVITY OF PLANT EXTRACTS AGAINST DERMATOPHYTES ANTIMYZETISCHE AKTIVITAET VON PFLANZENEXTRAKTEN GEGEN DERMATOPHYTEN" MYCOSES, BLACKWELL, BERLIN, DE, vol. 42, no. 11/12, December 1999 (1999-12), pages 665-672, XP001182623 ISSN: 0933-7407 tables 1-3 page 670, right-hand column, last paragraph page 670, left-hand column, last paragraph --- -/--	1,54,59, 71,72, 74-76, 83,84

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

7 October 2004

Date of mailing of the international search report

21/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Beranová, P

**THIS PAGE BLANK (USPTO)**

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI  Section Ch, Week 199002  Derwent Publications Ltd., London, GB;  Class B05, AN 1990-011023  XP002298463  &amp; JP 01 290619 A (HOKKAIDO TOGYO KK),  22 November 1989 (1989-11-22)  abstract</p>	1,16,54, 66,71
X	<p>DATABASE WPI  Section Ch, Week 199913  Derwent Publications Ltd., London, GB;  Class B04, AN 1999-148433  XP002298464  &amp; JP 11 012122 A (POLA CHEM IND INC),  19 January 1999 (1999-01-19)  abstract</p>	1,16,59, 66,71
X	<p>GB 14768 A A.D. 1911 (KOEHLER JOHAN  ROBERT) 9 November 1911 (1911-11-09)  page 3, line 10 - line 12</p>	1,16,54, 66
X	<p>US 2003/008021 A1 (HOWELL M TERRENCE ET  AL) 9 January 2003 (2003-01-09)  claims 1,4  page 4, paragraph 39</p>	1,16
X	<p>EP 1 031 348 A (KAO CORP)  30 August 2000 (2000-08-30)  examples 3,5,7-9</p>	1,54,59, 67,71
Y	<p>EP 0 093 563 A (KOWA CO)  9 November 1983 (1983-11-09)   claims</p>	1,16,31, 40,51, 52,54, 58-89
Y	<p>US 4 474 798 A (INAGI TOSHIO ET AL)  2 October 1984 (1984-10-02)   claims</p>	1,16,31, 40,51, 52,54, 58-89
Y	<p>EP 0 824 913 A (BEIERSDORF AG)  25 February 1998 (1998-02-25)   claims 1,2</p>	1,16,31, 40,51, 52,54, 58-89
Y	<p>WO 02/26761 A (KRASUTSKY PAVEL A ; UNIV  MINNESOTA (US); CARLSON ROBERT M (US))  4 April 2002 (2002-04-04)   claims</p>	1,16,31, 40,51, 52,54, 58-89

-/--

**THIS PAGE BLANK (USPTO)**



## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GB 2 051 575 A (SYNTHELABO) 21 January 1981 (1981-01-21)  claims 1,3 -----	1, 16, 31, 40, 51, 52, 54, 58-89

**THIS PAGE BLANK (USPTO)**

**Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 83 and 85 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 03092712	A	13-11-2003	WO	03092712 A1	13-11-2003
JP 1290619	A	22-11-1989	NONE		
JP 11012122	A	19-01-1999	NONE		
GB 191114768	A	09-11-1911	NONE		
US 2003008021	A1	09-01-2003	CA	2450478 A1	03-01-2003
			EP	1423132 A2	02-06-2004
			WO	03000185 A2	03-01-2003
			US	2003113393 A1	19-06-2003
			US	2004115290 A1	17-06-2004
			US	2004151792 A1	05-08-2004
EP 1031348	A	30-08-2000	JP	2000309524 A	07-11-2000
			EP	1031348 A2	30-08-2000
			JP	2000309528 A	07-11-2000
			US	2003129265 A1	10-07-2003
			US	2003129266 A1	10-07-2003
			US	2002106415 A1	08-08-2002
			US	2001031285 A1	18-10-2001
EP 0093563	A	09-11-1983	JP	1768330 C	30-06-1993
			JP	3045044 B	09-07-1991
			JP	58189115 A	04-11-1983
			CA	1194801 A1	08-10-1985
			DE	3372066 D1	23-07-1987
			EP	0093563 A2	09-11-1983
			US	4474798 A	02-10-1984
US 4474798	A	02-10-1984	JP	1768330 C	30-06-1993
			JP	3045044 B	09-07-1991
			JP	58189115 A	04-11-1983
			CA	1194801 A1	08-10-1985
			DE	3372066 D1	23-07-1987
			EP	0093563 A2	09-11-1983
EP 0824913	A	25-02-1998	DE	19633012 A1	19-02-1998
			EP	0824913 A2	25-02-1998
			JP	10087470 A	07-04-1998
WO 0226761	A	04-04-2002	AU	9495301 A	08-04-2002
			CA	2424013 A1	04-04-2002
			EP	1322661 A1	02-07-2003
			JP	2004509972 T	02-04-2004
			WO	0226761 A1	04-04-2002
			US	2004072807 A1	15-04-2004
			US	2002128210 A1	12-09-2002
GB 2051575	A	21-01-1981	FR	2460136 A1	23-01-1981
			AT	369264 B	27-12-1982
			AT	350580 A	15-05-1982
			BE	884190 A1	05-01-1981
			CH	647787 A5	15-02-1985
			DE	3025223 A1	08-01-1981
			ES	8103974 A1	01-07-1981
			GR	69637 A1	06-07-1982

**THIS PAGE BLANK (USPTO)**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2051575 A		IE 50062 B1	05-02-1986
		IT 1132510 B	02-07-1986
		LU 82583 A1	08-10-1980
		NL 8003871 A	07-01-1981
		PT 71495 A	01-08-1980
<hr/>			

**THIS PAGE BLANK (USPTO)**